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This unit presents methods to assess the immunosuppressive properties of
immunoregulatory cells of myeloid origin, such as myeloid-derived suppressor
cells (MDSCs), both in vitro and in vivo in mice, as well as in biological
samples from cancer patients. These methods could be adapted to test the
impact of different suppressive populations on T cell activation, proliferation,
and cytotoxic activity; moreover, they could be useful to assess the influence
exerted by genetic modifications, chemical inhibitors, and drugs on immune
suppressive pathways C© 2018 by John Wiley & Sons, Inc.
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INTRODUCTION
MDSCs are immature myeloid cells with potent immune suppressive activity that are
characterized by a pathological state of activation (Bronte et al., 2016; Gabrilovich et al.,
2007).
Two major subsets of MDSCs have been classified based on their phenotypic and mor-
phological features: monocytic (M)-MDSCs and polymorphonuclear (PMN)-MDSCs.
In mice, MDSCs described in the past as CD11b+ and Gr-1+ cells (Bronte et al., 2000;
Dolcetti et al., 2010) are now better identified as CD11b+Ly6ChiLy6G- (M-MDSCs) and
CD11b+Ly6CloLy6G+ (PMN-MDSCs) (Bronte et al., 2016; De Sanctis, Bronte, & Ugel,
2016a; Dolcetti et al., 2010; Movahedi et al., 2008; Peranzoni et al., 2010).
In cancer patients, the characterization of MDSCs is more complex, although it is cur-
rently accepted that three main subsets of circulating MDSCs exist, i.e., M-MDSCs and
PMN-MDSCs, while a more immature population, whose counterpart in the mouse is
not known, is defined as early-stage MDSCs (eMDSCs). Each of these subsets have been
characterized by different combinations of myeloid markers and contain more than a
single phenotype (Bronte et al., 2016; Damuzzo et al., 2015). Moreover, a recent study
demonstrated that human MDSCs, under different conditions, can express additional
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markers such as CD38, LOX-1, and PD-L1, highlighting their great plasticity and adding
additional layers of complexity to MDSC characterization and targeting (Tcyganov,
Mastio, Chen, & Gabrilovich, 2018).
Basic Protocol 1 shows how to isolate MDSCs from spleens of tumor-bearing mice, and
Basic Protocol 2 illustrates how to generate MDSCs from mouse bone marrow (BM)
samples. MDSCs obtained using these protocols can be assessed for their ability to
suppress T cell proliferation in response to antigen-specific activation (Basic Protocol
3) or following nonspecific stimulation (Basic Protocol 4). Basic Protocol 5 shows how
to assess T cell cytotoxic effector function in response to antigen-specific activation,
and therefore a Support Protocol describing the calculation of results is included. A
method to evaluate in vivo–induced immune suppression in mice is also presented (Basic
Protocol 6).
Basic Protocol 7 indicates how to isolate circulating human CD14+ cells enriched in M-
MDSCs. Basic Protocol 8 illustrates how to expand in vitro human bone marrow–derived
MDSCs (BM-MDSC), and Basic Protocol 9 describes how to test these cells for their
suppressive function on T cell proliferation.
PMN-MDSCs share the expression of the markers CD11b, CD15, (or CD66b+) and
CD33 with neutrophils, but differ in their buoyant density, since PMN-MDSCs can
be isolated in low-density Ficoll-gradient fraction, while neutrophils are present in the
high-density fraction. Thus, the addition of a specific marker is warranted to obtain
an enrichment of PMN-MDSCs. In this regard, we demonstrated that CD124 is up-
regulated both in M-MDSCs and in PMN-MDSCs, although its presence only correlates
with an immunosuppressive phenotype in M-MDSCs but not PMN-MDSCs of tumor-
bearing patients. However, the isolation of CD124-positive versus -negative cells is
technically challenging, since the staining of this antigen has a low intensity and a
unimodal expression, thus making the separation of a highly enriched CD124+ population
difficult to achieve. More recently, lectin-type oxidized LDL receptor 1 (LOX-1) has been
proposed as a marker to distinguish human neutrophils from PMN-MDSCs without the
use of a density gradient (Condamine et al., 2016).
All the in vitro protocols were optimized for microcultures in order to reduce the number
of cells to be used.
NOTE: All protocols using live animals must first be reviewed and approved by an
Institutional ethics committee and must be executed in accordance with governing laws,
directives, and guidelines.
NOTE: Patients must provide their informed consent and Institutional ethics committees
must approve all experiments with human samples.
NOTE: All solutions and equipment coming into contact with cells must be sterile, and
proper aseptic technique must be used accordingly.
NOTE: All incubations are performed in a humidified 37°C, 5% CO2 incubator unless
otherwise noted.
BASIC
PROTOCOL 1
ISOLATION OF MYELOID CELL SUBSETS FOR MEASUREMENT OF
IMMUNOSUPPRESSIVE ACTIVITY
This protocol is optimized to isolate MDSCs from the spleens of tumor-bearing mice,
preserving their functional activity in order to be used for both in vitro and in vivo
functional assays. It allows the high- purity separation of PMN-MDSCs and M-MDSCs
by FACS sorting, as required for the accurate immunosuppressive assays described hereSolito et al.
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Figure 1 Gating strategy to isolate mouse MDSC using flow cytometric sorting. Cell suspension from tissues
(spleen, blood, or tumor) of tumor-bearing mice or in vitro–differentiated BM cells were stained with the following
mix: anti-Ly6C, anti-ly6G, anti-CD11b and live–dead probe. The figure illustrates isolation of the two main MDSC
subsets derived by sequential steps: a morpho gate, a viability gate, a myeloid gate, and an MDSC gate. The
procedure makes it possible to isolate M-MDSCs and PMN-MDSCs with a purity of 80% to 90%.
and the molecular analysis protocols. In Figure 1, the gating strategy and an example of
separation are presented.
For tumor models in which low percentages of CD11b+ cells accumulate in the spleen, the
purity of MDSCs obtained could be lower; titration of antibodies and reagents may help
in obtaining better results. Moreover, a pre-enrichment step through immunomagnetic
sorting using specific CD11b microbeads could be coupled with this protocol according
to the manufacturer’s instructions (see mouse and human CD11b MicroBeads, Miltenyi).
This might improve the results, but it might also affect the viability and performance of
the sorted cells.
This protocol could be applied to separate myeloid subsets in lymphoid organs other
than spleen (i.e., bone marrow and lymph nodes) or from the tumor mass; however, an
organ might present some peculiarities due to its structure (for example, it is necessary to
digest the tumor to obtain a single-cell suspension) or function (for example, lymph nodes
contain lower amounts of myeloid cells), which might limit either purity or viability of
the recovered cell fractions.
This protocol has been used to successfully isolate different fractions of MDSCs from
C26GM and 4T1 tumor-bearing BALB/c mice, and from MCA203 and MN-MCA1
tumor-bearing C57BL/6 mice. The protocol can be used to separate splenocytes of mice
bearing tumors of different type and histology, provided that they induce an expansion
of MDSCs. High purity is less likely to be achieved with low percentages of MDSCs.
The same protocol has also been used to separate MDSC subsets obtained from bone
marrow-derived MDSCs, in vitro–generated, as previously reported (Marigo et al., 2010)
and as described in Protocol 2.
Previously, we published (Peranzoni et al., 2010; also see previous version of this unit;
doi: 10.1002/0471142735.im1417s91) a separation protocol that described how to obtain
three different subsets of myeloid cells from the spleens of tumor-bearing mice, by
immunomagnetic sorting. A commercial Miltenyi kit is now available for this separation
based on Gr-1 marker expression, which allows the separation of PMN-MDSCs as Gr-
1high cells (corresponding to Ly6Ghigh cells) and M-MDSCs as Gr-1dim Ly6G- containing
different proportions of Ly-6Chigh and Ly-6Clow cells dependent on the tumor models
used, and a fraction enriched in macrophage precursors within the Gr-1lowLy-6Clow Solito et al.
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Ly-6G-CD11b+. This protocol is still valid in cases in which a FACS sorter is not
available and when highly pure populations are not required.
Materials
Spleens from BALB/c or C57BL/6 tumor-bearing mice (mice purchased from
Jackson Laboratories) or in vitro-generated MDSCs (see Basic Protocol 2)
RPMI containing 3% FBS (see recipe)
Red cell ACK lysis buffer (Lonza)
Dulbecco’s phosphate-buffered saline (DPBS; Lonza BioWhittaker, cat. no.
BE17-515Q), cold
Fc-receptor (FcR) blocking reagent (clone 2.4G2, ThermoFisher)
Sorting buffer (see recipe) fixable viability stain
Fixable Viability Dye (ThermoFisher)
Anti mouse-CD11b (ThermoFisher)
Anti mouse-Ly6G (ThermoFisher)
Anti mouse-Ly6C (ThermoFisher)
Fetal bovine serum (FBS), heat inactivated
RPMI containing 10% FBS (see recipe)
10-mm culture dish
2-ml syringe
15- and 50-ml conical tubes
Centrifuge
100-μm nylon-mesh cell strainer (BD Biosciences)
MoFlo Astrios cell sorter (Beckman Coulter)
LSRII flow cytometer (BD Biosciences)
FlowJo 7.6.5 Software (TreeStar)
Additional reagents and equipment to harvest spleens from mice (see Reeves &
Reeves, 1992) and to determine cell number using trypan blue dye exclusion
(Strober, 2001)
NOTE: All antibodies need to be titrated. When working with more than one spleen and
different amounts of cells adapt reagent volume accordingly.
Process spleen(s)
1. Collect spleens of tumor-bearing mice (Reeves & Reeves, 1992) in a small volume
of RPMI containing 3% FBS under sterile conditions.
Take care to clean spleen from surrounding fibrous tissue.
2. Place spleen in a 10-mm culture dish with a small volume of RPMI containing 3%
FBS and gently disaggregate using the plunger of a 2-ml syringe.
If more than one spleen has to be collected to perform more tests, spleens can be stored
in a small volume of RPMI containing 3% FBS in a 50-ml conical tube on ice.
3. Add 5 ml of RPMI containing 3% FBS to cells and, pipetting gently, collect the cells
in a 50-ml conical tube. Repeat steps 2 and 3 until the complete disaggregation of
the spleen has been achieved.
4. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
The supernatant may be discarded by decantation or aspiration.
5. Lyse red blood cells by adding a volume of 5 ml (for each spleen) of red cell ACK
lysis buffer to the pelleted cells, and incubate at room temperature for 4 min.
6. Add a volume of RPMI containing 3% FBS equal to at least five times the volume
of lysis buffer added, and mix by gently pipetting up and down.Solito et al.
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7. Centrifuge the suspension 6 min at 300 × g, 4°C, and discard the supernatant.
8. Resuspend cell pellet in 10 ml/spleen of RPMI containing 3% FBS, filter through a
cell strainer (or a single sheet of nylon mesh) placed on the top of a 50-ml tube, and
collect the suspension.
Filtration can be helped by pre-hydrating the nylon mesh with a small volume of medium.
9. Properly dilute an aliquot of the single-cell suspension with trypan blue solution
(Strober, 2001) and estimate the number of viable cells, avoiding red blood cell
counts.
Trypan blue colors dead cells a faint blue, and these cells should not be taken into
account. Red blood cells can be recognized as small cells with a round shape and a neat,
thick perimeter.
Separation of PMN-MDSCs and M-MDSCs from splenocytes
An example of gating strategy for the sorting and results analyzed with FlowJo 7.6.5
Software is shown in Figure 1.
10. Transfer 1 × 108 viable cells obtained from the spleens of tumor-bearing mice to a
new 15-ml conical tube, and then add 8 to 10 ml of DPBS to wash the cells.
In the case of spleens coming from mice with completely unknown tumors, the proportion
of myeloid cells should be evaluated before staining a large sample.
11. Centrifuge the suspension 6 min at 300 × g, 4°C, and discard the supernatant.
12. Add 10 ml of sorting buffer and wash cells by gently pipetting up and down.
13. Centrifuge the suspension 6 min at 300 × g, 4°C, and discard the supernatant.
These fractions can be used to assess their immunosuppressive activity either in vitro
and in vivo.
14. Incubate samples with 10 μl Fc-receptor blocking reagent in 50 μl of sorting buffer
at room temperature for 10 min.
15. Add the mixture of antibody, composed of Fixable Viability Dye (5 μl), anti-CD11b
(10 μl), anti Ly6G (10 μl), and anti Ly6C (10 μl), to the tubes and incubate at
4°C for 20 min. Adjust the volume of staining mix to 100 μl with the sorting
buffer. Specifically, for FACS analysis, cells are stained in 15-ml polypropylene
tubes previously coated for at least 1 hr with heat-inactivated fetal bovine serum.
16. Wash twice with sorting buffer. Centrifuge the suspension 6 min at 300 × g, 4°C,
and discard the supernatant.
17. After labeling, resuspend samples at the concentration of 30 × 106 cells/ml of
sorting buffer and proceed with the FACS separation as outlined in Figure 1.
18. Filter MDSCs through a 100-µm cell strainer and isolate through MoFlo Astrios.
Sorting should be performed with a 100-μm nozzle, setting the pressure, voltage, and
cell rate as appropriate for the sorter.
19. Collect sorted M-MDSCs and PMN-MDSCs in two different 15-ml polypropylene
tubes previously coated for at least 1 hr with heat-inactivated fetal bovine serum.
20. After the separation, wash and resuspend M-MDSCs and PMN-MDSCs in 10 ml
of RPMI/10% FBS. Take an aliquot of the single-cell suspension, dilute it properly
with trypan blue solution, and estimate the number of viable cells (Strober, 2001).
Another aliquot is checked for purity with the LSRII flow cytometer. Solito et al.
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NOTE: All the procedures, including the sorting, are performed at 4°C, to avoid cell loss
and adherence to the plastic.
These fractions can be stained to assess the presence and distribution of markers that
were used to characterize mouse MDSCs (Table 1).
BASIC
PROTOCOL 2
MOUSE BM-MDSC GENERATION
This protocol is optimized to obtain bone marrow (BM)–derived MDSCs from mice
as previously described (Marigo et al., 2010). BM cells are cultured for 4 days in the
presence of the recombinant mouse cytokines GM-CSF and IL-6. The final cultures will
contain proportions of PMN-MDSCs, M-MDSCs, and macrophages.
Materials
C57BL/6 mice (The Jackson Laboratory)
RPMI containing 3% FBS (see recipe)
Red cell ACK lysis buffer (Lonza)
RPMI containing 10% FBS (see recipe)
Premium Grade IL-6 (Miltenyi Biotec)
Premium Grade GM-CSF (Miltenyi Biotec)
DPBS without Ca or Mg (Lonza BioWhittaker, cat. no. BE17-515Q) containing 2
mM EDTA
Scissors and pliers
2-ml syringe with 26-G needle
15- and 50-ml conical tubes
Centrifuge
100-μm nylon-mesh cell strainer (BD Biosciences)
6-well culture dishes
Additional reagents and equipment to harvest bone marrow from mice (Reeves &
Reeves, 1992) and to determine cell number using trypan blue dye exclusion
(Strober, 2001)
Process bone marrow (BM)
1. Remove tibias and femurs from mice, and remove the muscle from the bones with
scissors.
Take care to avoid hair contamination
2. Cut the extremity of the bones with pliers and scissors under sterile conditions.
3. Flush the medium inside the bones with a small volume of RPMI containing 3%
FBS, gently injected with a 2-ml syringe with a 26-G needle. Collect flushed-out
material in 50-ml conical tubes containing 5 ml of RPMI containing 3% FBS
BM-MDSC generation
4. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
The supernatant may be discarded by decantation or aspiration.
5. For two legs, lyse red blood cells by adding a volume of 5 ml of red blood cell lysis
buffer to the pelleted cells, and incubate at room temperature for 4 min.
6. Add a volume of RPMI/3% FBS equal to at least five times the volume of lysis
buffer added, and mix by gently pipetting up and down.
7. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
Solito et al.
6 of 42
Current Protocols in Immunology
Ta
bl
e
1
Co
m
m
on
m
Ab
s
Us
ed
fo
r
Ch
ar
a
ct
er
iz
a
tio
n
o
fS
ur
fa
ce
M
ol
ec
ul
es
in
M
ou
se
M
D
SC
s
Ep
ito
pe
Cl
on
e
A
nt
ib
od
y
ty
pe
Co
m
pa
ny
Ex
pr
es
sio
n
CD
11
b
M
1/
70
R
at
Ig
G
2b
,κ
Th
er
m
oF
ish
er
+
G
r-1
R
B
6-
85
C
R
at
Ig
G
2b
,κ
B
io
le
ge
nd
+
Ly
6G
1A
8
R
at
Ig
G
2a
,κ
Th
er
m
oF
ish
er
±
Ly
6C
M
k1
.4
R
at
Ig
M
,κ
Th
er
m
oF
ish
er
±
CD
11
5
A
FS
98
R
at
Ig
G
2a
,κ
Th
er
m
oF
ish
er
Lo
w
/−
CD
16
/C
D
32
2.
4G
2
R
at
Ig
G
2b
,κ
B
D
Ph
ar
m
in
ge
n
+
CD
12
4
(IL
-4R
α
)
m
IL
4R
-M
1
R
at
Ig
G
2a
,κ
B
D
Ph
ar
m
in
ge
n
±
CD
40
3/
23
R
at
Ig
G
2a
,κ
B
D
Ph
ar
m
in
ge
n
−
CD
80
16
-1
0A
1
A
rm
en
ia
n
H
am
st
er
Ig
G
2,
κ
B
D
Ph
ar
m
in
ge
n
+
CD
86
G
L1
R
at
Ig
G
2a
,κ
B
D
Ph
ar
m
in
ge
n
−
M
H
C-
I(
H
-2
K
d)
SF
1-
1.
1
M
o
u
se
Ig
G
2a
,κ
B
D
Ph
ar
m
in
ge
n
+
M
H
C-
I(
H
-2
K
b)
A
F6
-8
8.
5
M
o
u
se
Ig
G
2a
,κ
B
D
Ph
ar
m
in
ge
n
+
M
H
C-
II
2G
9
R
at
Ig
G
2a
,κ
B
D
Ph
ar
m
in
ge
n
−
CD
31
39
0
R
at
Ig
G
2a
,κ
B
io
le
ge
nd
+/
Lo
w
/−
F4
/8
0
A
3-
1
R
at
Ig
G
2b
Se
ro
te
c
Lo
w
/−
CD
2
R
M
2-
5
R
at
Ig
G
2a
,λ
B
D
Ph
ar
m
in
ge
n
Lo
w
/−
CD
71
R
I7
21
7
R
at
Ig
G
2a
,κ
B
io
le
ge
nd
Lo
w
/−
CD
11
c
N
41
8/
H
L3
A
rm
en
ia
n
H
am
st
er
Ig
G
/A
rm
en
ia
n
H
am
st
er
Ig
G
1,
λ
2
B
io
le
ge
nd
/B
D
Ph
ar
m
in
ge
n
Lo
w
/−
ER
-M
P5
8
ER
-M
P5
8
R
at
Ig
M
Se
ro
te
c
+
Solito et al.
7 of 42
Current Protocols in Immunology
8. Resuspend the cells obtained from two legs in 5 ml of RPMI containing 10% FBS
and filter the suspension through a cell strainer.
The volume can be scaled to meet researchers’ needs; extra medium volume can also be
added to rinse the cell strainer, minimizing cell loss.
9. Take an aliquot of the single-cell suspension, dilute it properly with trypan blue
solution, and estimate the number of viable cells (Strober, 2001).
10. Adjust the concentration of the BM suspension to 1.5 × 106 cells/ml using
RPMI/10% FBS.
11. Plate 1 ml (1.5 × 106 cells) of BM cells in each well of a 6-well plate, add 2 ml
of RPMI/10% FBS in the presence of cytokines GM-CSF and IL-6, both at a final
concentration of 40 ng/ml (per well), and place the culture in a 37°C, 5% CO2
incubator for 4 days.
12. At day 4 of culture, to test the immunosuppressive properties of the cells, gently
harvest BM-MDSCs with a Pasteur pipette. Wash dishes with DPBS containing 2
mM EDTA to detach and collect the remaining cells.
BASIC
PROTOCOL 3
MEASURING MYELOID-INDUCED SUPPRESSION OF T CELL
ANTIGEN-INDUCED PROLIFERATION IN VITRO BY CELL TRACE
DILUTION
Immune suppression exerted by myeloid cells to the detriment of activated T cells can
be measured in terms of inhibition of proliferation by evaluating dye dilution to trace
multiple generations of proliferating lymphocytes.
Materials
Immunosuppressive cells, e.g., MDSCs (Basic Protocol 1 or 2)
RPMI containing 10% FBS (see recipe)
CD45.1 congenic mice; purchased from Jackson Laboratories, under the name
B6.SJL-PtrcaPepcb/BoyJ.
Transgenic OT-1 mice on a C57BL/6 background bearing a αβ T cell receptor
(TCR) that recognizes the Kb-restricted OVA257-264 peptide; purchased from
Jackson Laboratories, under the name C57BL/6-Tg (TcraTcrb)1100Mjb/J)
Red cell ACK lysis buffer (Lonza)
RPMI containing 3% FBS (see recipe)
Dulbecco’s phosphate-buffered saline (DPBS without Ca and Mg; Lonza
Biowhittaker, cat. no. BE17-515Q)
CellTraceTM Violet Cell Proliferation Kit (Molecular Probes)
Fetal bovine serum (FBS)
10 mg/ml OVA257-264 peptide stock solution (available lyophilized from JPT
Peptide Technologies)
Staining buffer (see recipe)
Fc-receptor (FcR) blocking reagent (clone 2.4G2, ThermoFisher)
Anti-CD8 (i.e., PeCy5-anti CD8a, clone 53.6.7, cat. # 15-0081-81, ThermoFisher)
Anti-CD45.2 conjugated to a brilliant fluorochrome (i.e., PE-anti CD45.2, clone
104, cat. # 12-0454-81, ThermoFisher)
96-well or 384-well flat-bottom plates
10-mm culture dish
2-ml syringe
50-ml conical tube
Refrigerated centrifuge
100-μm nylon-mesh cell strainer (BD Biosciences)Solito et al.
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LSRII flow cytometer (BD Biosciences)
FlowJo 7.6.5 Software (TreeStar)
4-ml round-bottom tubes
TruCount Tubes (Becton Dickinson)
Additional reagents and equipment to prepare immunosuppressive cells (Basic
Protocol 1 and 2), harvest spleens from mice (Reeves & Reeves, 1992), and
count viable cells by trypan blue exclusion (Strober, 2001)
Day 0: Suppressive cell plating
1. Prepare MDSCs, according to Basic Protocol 1 or 2.
2. Wash cells twice in RPMI medium containing 10% FBS and resuspend in a suitable
volume of RPMI containing 10% FBS.
3. Dilute an aliquot of suspension in trypan blue solution and determine viable cell
concentration (Strober, 2001).
4. Adjust cell concentration appropriately with RPMI/10% FBS.
The concentration will depend upon the design of the experiment. A good range of
MDSCs is 1.5% to 24% of the effector culture cellularity. For the 96-well plate, if
0.6 × 106 effector cells are used, MDSC concentration can be adjusted to 1.44 × 106/ml,
so that 0.144 × 106 cells will be plated in 100 μl (24% of the effector cells). For the
384-well plate, MDSC concentration can be adjusted to 0,6× 106/ml, so that 24,000 cells
will be plated in 40 μl (24% of the effector cells).
For example, in the 96-well plate, if the experimental setup requires 3% of suppressive
cells in the coculture and effector splenocytes are 0.6 × 106 cells/well, 0.018 × 106
suppressive cells will be plated per well. Adjust suppressive cell concentration to 0.18 ×
106 cells/ml and plate 100 μl/well.
5. Plate myeloid cells in triplicate in a 96-well flat-bottom microplate in a volume of
100 μl (or 40 μl for 384-well plate) of RPMI/10% FBS, and place the microplate
in a 37°C, 5% CO2 incubator for at least 30 min.
This assay requires a careful titration of the suppressive cells. The number of suppressor
cells to add to each well will depend on the experimental plan. A good starting point
could be to plate suppressor cells at 24% of the total cells in control cultures and serially
dilute them by a factor of 2 until they represent 1.5% of total cells. When organizing
the distribution of samples, avoid using the outer wells, because these wells are more
susceptible to evaporation. Outer wells can be filled with RPMI containing 3% FBS.
Remember to fill at least three wells with RPMI/10% FBS without myeloid suppressor
cells, to use as control cultures.
Plating splenocytes
6. Separately collect spleens from both CD45.1 and OT-1 mice (Reeves & Reeves,
1992) in a small volume of RPMI/3% FBS under sterile conditions.
Splenocytes from OT-1 mice need to be diluted with CD45.1 splenocytes to obtain a
concentration of OVA-specific CD8+ T lymphocytes, which is 1% of total cultured cells
(usually about 1:10 dilution is sufficient). Consequently, one spleen from OT-1 mice is
sufficient for several microtiter plates. The percentage of specific OVA CD8+ T lympho-
cytes in total splenocytes can be determined before their use by cytometry staining with
anti-CD8 and anti-Vα2 Vβ5.1/5.2 mAbs to identify the specific T cell receptor (TCR).
7. Place spleens in a 10-mm culture dish with a small volume of RPMI/3% FBS, and
gently disaggregate using the plunger of a 2-ml syringe.
8. Add 5 ml of RPMI/3% FBS to cells and collect the cells in a 50-ml conical tube by
gently pipetting up and down. Repeat steps 7 and 8 until the spleen is completely
disaggregated. Solito et al.
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9. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
10. Lyse red blood cells by adding about 5 ml of red cell lysis buffer for spleen, and
incubate at room temperature for 4 min.
11. Add a quantity of RPMI/3% FBS equal to at least five volumes the quantity of lysis
buffer applied, and mix by gently pipetting up and down.
It is very important to obtain a red blood cell–free suspension (see explanation in
Commentary).
12. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
13. Resuspend cells in 1 ml of RPMI/10% FBS, and put on ice.
14. Wash both CD45.1 and OT-1 cells by adding 10 ml of RPMI/10% FBS.
15. Centrifuge the suspensions 6 min at 300 ×g, 4°C, and discard the supernatant.
16. Resuspend the cells in 2 ml/spleen of RPMI/10% FBS, and filter the suspension
through a cell strainer.
17. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell
concentration (Strober, 2001).
18. Keep CD45.1 splenocytes on ice and wash OT-1 cells twice by adding 10 ml of
ice-cold DPBS (4°C) and discarding the supernatant.
19. Adjust OT-1 splenocyte concentration to 20× 106 cells/ml concentration with room
temperature DPBS and add an equal volume of DPBS containing CellTraceTM at
the concentration of 5 μM (the final concentration of the suspension will be equal
to half the concentration). Keep the suspension 5 min at 37°C in incubator and mix
every minute.
20. Block the staining by adding an equal volume of FBS and keep at room temper-
ature for 1 min. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the
supernatant.
21. Wash cells twice in DPBS with 10% FBS and resuspend in 5 ml of RPMI.
22. Check the staining with CellTraceTM by flow cytometry.
When evaluating CellTrace incorporation, a control for autofluorescence value of un-
stained splenocytes should be included, to evaluate whether the difference in emission
signals among unstained splenocytes and CellTrace+ splenocytes is enough to be able to
quantify extensive proliferation, which will bring a strong dilution of CellTrace signal. A
successful staining is achieved when the histogram has a single, narrow peak.
23. Adjust the concentration of both the CD45.1 and the OT-1 splenocyte suspensions
to 12 × 106 cells/ml for 96-well plate (or at 5× 106 cells/ml for 384 wells/plate) in
RPMI/10%.
24. Mix CD45.1+ and CellTrace+ OT-1 cells in appropriate proportions to obtain a
concentration of OVA-specific CD8+ T lymphocytes that is 1% of the total culture,
and add OVA257-264 peptide to a final concentration of 1 μg/ml.
CD8+OVA-TCR+ percentage in OT-1 mice can be determined by FACS analysis using a
simple staining with anti-CD8α and anti-anti-Vα2 Vβ5.1/5.antibodies. CD8+OVA-TCR+
double-positive cells are usually about 10% of total splenocytes in these transgenic mice,
while the same cell population is almost negligible in wild-type C57BL/6 or congenic
CD45.1 mice. In order to obtain a cell suspension with 1% CD8+OVA-TCR+ cells, 1
part of OVA splenocytes (with 10% CD8+OVA-TCR+cells) can be added to 9 parts of
CD45.1+ splenocytes (with 0% CD8+OVA-TCR+cells).Solito et al.
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25. Immediately plate 50 μl per well of cell suspension onto the previous 96-well plate
containing the immunosuppressive myeloid cells (step 5), or 20 μl per well if a
384-well plate was used.
26. Add 50 μl to 96-well plate (or 20 μl for 384-well plate) of RPMI/10% FBS contain-
ing OVA257-264 peptide at a final concentration in each well of 1 μg/ml. Incubate for
3 days in the 37°C, 5% CO2 incubator.
Day 3: Culture harvesting
27. Pool triplicate cultures to new 4-ml round-bottom tubes, wash samples once with
staining buffer, centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the
supernatant.
28. Block nonspecific binding with 50 μl FcR blocking reagent for 10 min at 4°C.
29. Stain cells with 50 μl of a mix composed of 0.5 μl of anti-CD8 and 0.1 μl of
anti-CD45.2 antibodies in 49 μl of staining buffer, for 20 min at 4°C.
Remember to include appropriate single-staining controls.
30. Wash samples once with staining buffer, centrifuge the suspension 6 min at 300 ×g,
4°C, and discard the supernatant.
31. Resuspend samples in 200 μl DPBS, transfer the mix in TruCount tubes, briefly
vortex and then proceed with flow cytometric acquisition and analysis.
Flow cytometric analysis
32. Perform flow cytometric acquisition and analysis.
To detect proliferating CD8+ T cells, gate cells first by their morphology, and then collect
a sufficient number of events in the CD8+/CD45.2+/CellTrace+ gate.
After the acquisition, proceed with data analysis. Gate cells by morphology and iden-
tify CD8+/CD45.2+/CellTrace+ population. Inside this gate, set a baseline gate on the
histograms of CellTrace signal of unstimulated splenocyte controls, and copy this gate
to the stimulated CD8 cells cultured in the presence or absence of MDSCs, in order to
determine the percentage of proliferating T lymphocytes. With FlowJo, it is the possible
to model proliferation data; FlowJo presents a graphical display as well as information
about each cell generation in the subset. The proliferation platform also provides infor-
mation about the fraction of cells from the original population that have divided and the
number of times these cells have divided. In addition, the FlowJo Proliferation Platform
draws gates that separate each cell generation.
Results obtained can be quantitative or qualitative. See Critical Parameters and Trou-
bleshooting.
BASIC
PROTOCOL 4
MEASURING MYELOID-INDUCED SUPPRESSION OF T CELL
PROLIFERATION IN VITRO BY ANTI-CD3/ANTI-CD28 STIMULATION AND
EVALUATION OF [3H]THYMIDINE ([3H]TdR) INCORPORATION
Proliferation of T cells can be induced by antigen-independent stimulation, and MDSCs
can exert immune suppressive functions on these cells. The proliferative arrest of actively
dividing cells can also be measured as a function of [3H]TdR incorporation by T cells
into their DNA. The method is extremely simple and provides a quantitative and rela-
tively rapid analysis, which can be easily applied to complex experiments as large-scale
screenings of drugs and treatments.
Materials
Dulbecco’s phosphate-buffered saline (DPBS; Lonza BioWhittaker, cat. no.
BE17-515Q) Solito et al.
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Anti-CD3 (2C11, ATCC)
Anti-CD28 (clone 37.5, ATCC)
Immunosuppressive (myeloid) cells, e.g., MDSCs (Basic Protocol 1 or 2)
RPMI containing 10% FBS (see recipe)
C57BL/6 mice purchased from Jackson Laboratories
RPMI containing 3% FBS (see recipe)
Red cell ACK lysis buffer (Lonza)
[3H]TdR (PerkinElmer)
Serum-free RPMI (e.g., Invitrogen)
Serum-free RPMI medium (e.g., Invitrogen)
96% ethanol
MicroScint-20 scintillation fluid (PerkinElmer)
96-well flat-bottom microtiter plate
10-mm culture dish2-ml syringe
50-ml conical tubes (BD Falcon)
Refrigerated centrifuge
100-μm nylon-mesh cell strainer (BD Biosciences)
Unifilter-96 GF/C plate (PerkinElmer) with plate sticker
96-well U-bottom microtiter plate (PerkinElmer)
Plate harvester: FilterMate 196 (Packard)
TopSeal-A 96-well microtiter plate adhesive sealers (PerkinElmer)
Scintillation counting device (TopCount, PerkinElmer)
Computer running spreadsheet program, e.g., Microsoft Excel
Additional reagents and equipment to prepare immunosuppressive cells (Basic
Protocol 1 or 2), harvest spleens from mice (Reeves & Reeves, 1992), and count
viable cells by trypan blue exclusion (Strober, 2001)
Day 0: Culture plate coating
1. Prepare sufficient coating buffer: DPBS containing anti-CD3 (3 μg/ml final concen-
tration) and anti-CD28 (2 μg/ml final concentration).
Antibody concentration may be optimized on the basis of stock and supplier; a suitable
volume would be 11 ml of antibody solution per plate.
2. Fill 96-well flat-bottom microtiter plates with 100 μl/well anti-CD3 and anti-CD28-
containing DPBS with a multichannel pipettor; also fill an equal number of wells with
100 μl/well of DPBS without antibodies, for nonspecific proliferation measurement.
Also remember to fill extra wells for appropriate controls based on the experimental set
up, e.g., suppressive cells only.
3. Incubate the plate overnight at 4°C.
Day 1: Cell plating
Plate immunosuppressive cells
4. Prepare myeloid (immunosuppressive) cells, e.g., MDSCs, according to Basic Pro-
tocol 1 or 2 or other strategies of enrichment.
5. Wash cells twice in RPMI containing 10% FBS and resuspend them in a suitable
volume of RPMI/10% FBS.
The supernatant should be aspirated from the top; be careful to remove as much super-
natant as possible without disturbing the cell pellet.
Solito et al.
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6. Resuspend cells in a small volume of RPMI/10% FBS. Dilute an aliquot of sus-
pension in trypan blue solution and determine viable cell concentration (Strober,
2001).
7. Adjust cell concentration appropriately with RPMI/10% FBS.
The concentration depends upon the design of the experiment. A good range of MDSCs
is 24% to 1.5% of the effector culture cellularity. If 0.6 × 106 effector cells are used,
MDSC concentration can be adjusted to 1.44 × 106/ml, so that 0.144 × 106 cells will be
plated in 100 μl (24% of the effector cells).
8. Working under sterile conditions, empty 96-well microtiter plate (from step 3) by
inverting it with a rapid movement.
Work under a laminar flow hood; a plastic basin wrapped with paper towels can be used
to discard the coating buffer.
9. Fill every well with 200 μl of DPBS using a multichannel pipettor and empty the
plate as in step 8. Repeat at least three times to wash extensively.
Fill the plate from the top of the well to avoid scratching the surface of the well, which
might disturb the antibody coating.
10. Immediately plate suppressive cells in triplicate for specific and background prolif-
eration in 100 μl of RPMI/10% FBS, and place the microtiter plate in a 37°C, 5%
CO2 incubator.
When organizing the distribution of samples, avoid using the outer wells, because these
wells are more susceptible to evaporation. Outer wells can be filled with sterile medium.
Remember to fill at least six wells with RPMI/10% FBS without suppressive cells; these
wells will be used as control cultures for the determination of specific and nonspe-
cific proliferation. Multiply these control wells for different treatments according to the
experimental setup, e.g., different inhibitors and drugs to be tested.
Plate splenocytes
11. Collect spleens from C57BL/6 mice (Reeves & Reeves, 1992) in a small volume of
RPMI containing 3% FBS under sterile conditions.
Usually one spleen from an 8-week old-mouse is sufficient for one plate.
12. Place spleens in a 10-mm culture dish with a small volume of RPMI/3% FBS and
gently disaggregate them using the plunger of a 2-ml syringe.
13. Add 5 ml of RPMI/3% FBS to cells and collect the cells in a 50-ml conical tube by
gently pipetting. Repeat steps 12 and 13 until complete disaggregation of the spleen
is achieved.
14. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
15. Lyse red blood cells by adding a volume of red cell ACK lysis buffer equal to the
volume of the pelleted cells, and incubate at room temperature for 4 min.
16. Add a volume of RPMI/3% FBS equal to at least five times the volume of lysis
buffer added, and mix by gently pipetting up and down.
17. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
18. Wash cells with 10 ml of RPMI/10% FBS.
19. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
20. Resuspend the cells in 2 ml of RPMI/10% FBS for each spleen and filter the
suspension through a cell strainer. Solito et al.
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The volume can be scaled to meet researchers’ needs; extra medium volume can also be
added to rinse the cell strainer, preventing cell loss.
21. Dilute an aliquot of the suspension in trypan blue solution and determine viable cell
concentration (Strober, 2001).
22. Adjust the concentration of the splenocyte suspension to 6 × 106 cells/ml with
RPMI/10% FBS.
23. Immediately plate 100 μl of cell suspension onto the previously coated microtiter
plate and incubate 3 days in the 37°C, 5% CO2 incubator.
Pay attention to the cell distribution schema. Splenocytes will proliferate upon anti-
CD3/anti-CD28 stimulation, and their proliferation will be inhibited by immunosup-
pressive cells; therefore, splenocytes should be distributed in previously anti-CD3/anti-
CD28-coated wells, either with or without immunosuppressive cells, as test and reference
wells, respectively. The proliferative behavior of MDSCs alone under these conditions
should also be tested; therefore, MDSCs will be cultured with 100 μl of medium instead
of effector cells.
[3H]TdR should be added the third day after culture setup. It would be useful to check the
cell culture daily in order to avoid medium exhaustion by excessive proliferation of cells
(signaled by medium turning yellow) or initial cell death (granular, small cells instead
of cell clumps).
Day 4
24. Add 1 μCi of [3H]TdR in 25 μl of serum-free RPMI to each well and incubate
18 hr in the 37°C, 5% CO2 incubator.
The concentration of the [3H]TdR solution added to each well will thus be 0.04 μCi/μl.
Day 5
Culture harvesting
25. Load a Unifilter-96 GF/C plate and an empty clean 96-well U-bottom plate onto
the plate harvester and prepare Unifilter-96 GF/C plate by washing it with distilled
water.
A wet Unifilter-96 GF/C is essential to obtain consistent results.
26. Load the culture plate onto harvester and aspirate culture medium, collecting it in
the “hot” radioactive waste tank.
27. Wash the plate five times with water and aspirate, collecting the supernatant in the
“hot” radioactive waste tank. Repeat another five times using aspiration, collecting
the supernatant in the “cold” radioactive waste tank.
28. Remove the culture plate from the harvester and replace it with a proper vessel filled
with 96% ethanol.
In this case, a proper vessel is a container, similar in dimensions to a 96-well plate, that
can be accommodated properly in the harvester; it could be, for example, a plate lid or
a pipet-tip box lid with the same length and width as a 96-well plate, deep enough to
contain 2 to 5 ml of alcohol.
29. Completely aspirate ethanol, collecting it in the “cold” radioactive waste tank.
30. Open the harvester and let the Unifilter-96 GF/C plate dry by continuous aspiration.
Plate dryness is essential to obtain consistent results, since the scintillation cocktail can
only be mixed with a very small amount of water and still perform correctly.
Solito et al.
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Preparation of Unifilter-96 GF/C plate for reading
31. Check plate dryness.
The Unifilter-96 GF/C plate can be observed against a light source; wells that are not
properly dried will appear translucent. Wait until the plates are completely dry.
32. Apply a plate sticker on the back of the Unifilter-96 GF/C plate.
Take care to properly position the sticker. Inappropriate positioning will result in leakage
of scintillation liquid.
33. Fill each well with 25 μl Microscint-20 with a multichannel pipettor.
Take care not to spill the liquid outside of the well rim, since this could hinder plate
sealing.
34. Seal the plate with TopSeal-A plate sealer.
35. Keep the plate in the dark for at least 30 min.
This step of incubation in the dark is necessary in order to quench the scintillation
cocktail.
36. Read the plate in a TopCount scintillation counting device for 1 min/well.
37. Interpret results.
Proliferation is represented in counts per minute (cpm), which is proportional to the
[3H]TdR that cells have incorporated in their DNA during the S phase of proliferation.
In a spreadsheet program like Excel, calculate average cpm from triplicate cultures and
subtract nonspecific proliferation. Also check for MDSC proliferation, which should be
minimal.
BASIC
PROTOCOL 5
MEASURING MYELOID CELL–INDUCED SUPPRESSION OF T CELL
CYTOTOXIC ACTIVITY IN VITRO: INHIBITION OF ANTIGEN-INDUCED
CYTOTOXIC ACTIVITY OF T CELLS IN MICROCULTURES
Immune suppression exerted by myeloid cells to the detriment of activated T cells could
also be measured in ways that can complement simply looking at the process of T cell
expansion. Assessing the cytotoxic activity of CD8+ T cells, elicited by antigen-specific
stimulation in vitro, will allow one to simultaneously assess both T cell abundance and
functional effector state.
Materials
Immunosuppressive cells, e.g., MDSCs (Basic Protocol 1 and 2)
RPMI containing 10% FBS (see recipe)
10 mg/ml OVA257-264 peptide stock solution (available lyophilized from JPT
Peptide Technologies)
EL4 cell line (ATCC TIB-39TM) maintained in culture in 75-cm2 culture flasks:
prepare a sufficient number of flasks containing EL4 cells, which need to be
subconfluent on day 5
Dulbecco’s phosphate buffered saline (DPBS without Ca or Mg; Lonza
BioWhittaker, cat. no. BE17-515Q)
Fetal bovine serum (FBS)
1 mCi/ml Na51CrO4 (PerkinElmer)
RPMI containing 5% FBS (see recipe)
Sodium dodecyl sulfate (SDS)
96-well flat bottom microplates
50-ml conical tubes Solito et al.
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Refrigerated centrifuge
12-ml round-bottom tubes
Microtiter plate carrier for centrifuge
LumaPlate (PerkinElmer)
Scintillation counting device (TopCount, PerkinElmer)
Additional reagents and equipment to prepare immunosuppressive cells (Basic
Protocol 1 or 2), to prepare splenocytes (Basic Protocol 3), and count viable
cells by trypan blue exclusion (Strober, 2001)
Day 0: Suppressive cell plating
Prepare myeloid (immunosuppressive) cells, e.g., MDSCs, according to Basic Protocol
1 or 2 and plate them by following the procedures (1 to 5) reported in Basic Protocol 3,
considering a 96-well flat-bottom microplate only.
Plating effector splenocytes
Prepare splenocytes according to Basic Protocol 3 from step from 6 to 18. Continue with
the steps below.
1. Adjust the concentration of both the CD45.1 and the OT-1 splenocyte suspensions
(prepared as described in Basic Protocol 3) to 6× 106 cells/ml for a 96-well plate in
RPMI/10% FBS.
2. Mix CD45.1 and OT-1 splenocytes in appropriate proportions to obtain a concen-
tration of OVA-specific CD8+ T lymphocytes, which is 1% of the total culture, and
add OVA257-264 peptide for a final concentration of 1μg/ml.
See Basic Protocol 3, step 24, for details.
3. Immediately plate 100 μl of splenocyte suspension onto the previous microplate
containing the immunosuppressive myeloid cells, and incubate for 5 days at 37°C,
in the 5% CO2 incubator.
Day 5: Target cell preparation
4. Collect EL4 in suspension cells from 75-cm2 flasks in a 50-ml conical tube.
5. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
6. Resuspend the cells in 5 ml of 10% FBS in DPBS.
7. Dilute an aliquot of suspension in trypan blue solution and determine viable cell
concentration (Strober, 2001).
8. Aliquot 6 × 106 cells to two new 12-ml round-bottom tubes. Bring volume to 10 ml
with 10% FBS in DPBS.
3 × 106 target cells are sufficient for at least 15 test plates. The quantity can be scaled
when necessary; nevertheless, if more than 3 × 106 cells are needed, prepare different
aliquots for the next steps.
9. Centrifuge the suspension 6 min at 300 × g, 4°C, and carefully discard the super-
natant.
In this step, it is essential to eliminate as much supernatant as possible, in order to
improve 51Cr uptake by target cells.
10. Add 10 μl of undiluted FBS to both pellets.
If you decide to load a smaller number of cells, simply scale down FBS to obtain a 10%
final concentration.
Solito et al.
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11. Add 3 μl of OVA257-264 peptide solution (10 mg/ml) to one of the two pellets (which
will be the pulsed sample).
One pellet will not receive the peptide and will be used as control for nonspecific lysis.
An EG7 cell line stably transfected to express the antigen OVA257-264 is also available.
These cells can also be used in the test to evaluate specific lysis.
12. Add 100 μl of 1 mCi/ml Na51CrO4 to each tube and resuspend by gentle flicking.
Avoid the formation of bubbles.
13. Incubate 1 hr at 37°C, flicking the tube every 15 min. After 1 hr, wash the cells
twice with RPMI containing 5% FBS, each time centrifuging the cells 10 min at 300
×g, room temperature, removing the supernatant, and then resuspending the cells
in 6 ml of RPMI/5% FBS. Determine viable cell concentration (Strober, 2001) and
adjust to 0.02 × 106 cells/ml with RPMI/5% FBS.
During the 1-hr target incubation, proceed with the rest of the protocol (step 14). If test
plates (step 14) are not ready when the target incubation ends, return washed target cells
to the incubator; it is extremely important to count and adjust target-cell concentration
just before plating them, to improve reproducibility.
Test plate setup
14. Fill new 96-well plate (test plate) with 100 μl/well of RPMI containing 5% FBS.
Resuspend cells in culture plate by gently pipetting up and down several times with
a multichannel pipettor, then transfer 50 μl of culture to the first row of the test
plate; pipet up and down five times to mix, and then transfer 50 μl of cells to the
subsequent rows, thus obtaining an 8-point, 1:3 serial dilution (Fig. 2).
Every well of the culture plate has to be diluted eight times; consequently, four different
culture conditions in triplicate could be arranged per each test plate. See Figure 2 as an
example. Remember that specific and nonspecific lysis need to be determined in separate
plates, because the same culture will be tested against peptide-pulsed and unpulsed
targets: therefore, every test plate has to be prepared in duplicate. Also, remember to
fill at least six wells in a separate plate (three for peptide-pulsed target cells and three
for unpulsed target cells) with RPMI containing 5% FBS and 1% SDS and six wells
with RPMI/5% FBS without any addition of culture cells, to evaluate maximum and
spontaneous 51Cr release of target cells, respectively.
15. Fill plates with 100 μl of either OVA257-264 peptide-pulsed or unpulsed EL4 cells
(see steps 12 to 14).
Remember to add peptide-pulsed and unpulsed target cells to wells set for maximum and
spontaneous release evaluation.
16. Using a centrifuge with a microtiter plate carrier, spin down cells for 10 sec at 300
×g, at room temperature, to bring the cells to the bottoms of the wells.
17. Incubate the plate 5 hr at 37°C in the, 5% CO2 incubator.
Reading test plates
18. With a multichannel pipettor, transfer 30 μl of supernatant from each well of the in-
cubated test plates to a PerkinElmer LumaPlate and let medium evaporate overnight.
The same row of tips can be used to transfer a full plate, starting from the bottom (more
diluted row) of the test plate to the top.
Solito et al.
17 of 42
Current Protocols in Immunology
AB
C
D
E
F
G
H
1 2 3 4 5 6 7 8 9 10 11 12
Test 1 Test 2 Test 3
Control culture
Suppressive cell
serial dilution
Culture Plate
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5
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5
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C
Figure 2 Sample protocol sheets for immunosuppressive assays. Design (A) allows measure-
ment of the suppressive activity of 5-fold serial dilution of myeloid cells/plate. Designs (B) and (C)
allow one to test the effector function of two lanes of cultures in plate A, with 8-fold serial dilutions.
19. Read LumaPlates in a TopCount scintillation counting device for 1 min/well.
Figure 2 shows a schematic representation of sample plating in the different steps of this
protocol.
Interpretation of results and calculation of lytic units
51Cr release due to lysis of target cells, measured by the TopCount device (see Basic
Protocols 4 and 5), is expressed in counts per minute (cpm). TopCount makes it possible
to set up reading protocols that can directly transform cpm values to percentage lysis,Solito et al.
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Table 2 Common mAbs Used for Characterization of Human CD11blow/– BM-MDSCs and PB
M-MDSCs
Epitope Clone Antibody type Company Expressiona
CD3 UUCHT1 Mouse IgG1, κ Beckman Coulter −
CD4 SK3 Mouse IgG1, κ BD Biosciences −
CD8 SK1 Mouse IgG1, κ BD Biosciences −
CD19 HIB19 Mouse IgG1, κ BD Biosciences −
CD56 NCAM16.2 Mouse BALB/c IgG2b, κ BD Biosciences −
CD11b Bear1 Mouse IgG1 Beckman Coulter Low/−
CD16 REA423 Recombinant human IgG1 Miltenyi Biotec −
CD124 25463 Mouse IgG2a R&D Systems +
CD14 M5E2 Mouse IgG2a, κ BD Biosciences +
HLA-DR L243 Mouse BALB/c IgG2a, κ BD Bioscience Low/−a
aCD11b and CD16 expressions refers to BM-MDSC, while CD124, CD14, and HLA-DR expressions refer to PB
M-MDSC.
and also calculate the average of triplicate measurements; calculations can otherwise be
performed with a software like Excel applying the following formula:
% lysis = cpmexperimental − cpmspontaneous
cpmmaximum − cpm spontaneous × 100
Results can be displayed in a line plot with the x axis representing culture dilution and the
y axis representing percentage of lysis. Nonspecific lysis, if any was detected, could be
subtracted from specific lysis point by point, or otherwise could be separately displayed.
Another way to represent the results, which is more straightforward and also makes
it possible to average more experiments, is the calculation of Lytic Units (L.U.). This
involves determination of the culture dilution necessary to obtain a given lysis percentage,
usually 30% (L.U.30) or 50% (L.U.50). Such determinations could be achieved using
any software allowing for nonlinear regression. Data are initially arranged in a table with
two columns, the first indicating the amount of culture applied to the test (on the basis of
the dilution), the other the percentage of specific lysis (see the two far-right columns of
Table3).
The amount of culture that gives a lysis of 30% can thus be determined by applying a
four-parameter logistic regression, or another of the proposed models, that better fit the
experimental results, obtaining a measurement of L.U.30. Normalize this number on a
per culture basis. To get the number of L.U.30 contained in the culture:
no. of L.U.30= 1L.U.30
Normalize the test culture against the control culture without myeloid suppressor cells:
% L.U.30=
no. of L.U.exper30
no. of L.U.ctrl30
This will give a measure of the percentage of L.U.30 in test culture compared to control
culture and represent a direct measure of how much inhibition is provided by the presence
of different numbers of myeloid suppressors. Amount of culture in the first column can Solito et al.
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Table 3 Example of the Determination of the Culture Dilution Necessary to Obtain a Given Lysis
Percentagea
Dilution number Amount of culture Percent lysis
1st 1.00E+00 97
2nd 3.33E-01 83
3rd 1.11E-01 80
4th 3.70E-02 60
5th 1.23E-02 31
6th 4.12E-03 15
7th 1.37E-03 7
8th 4.57E-04 4
aRegarding the amount of culture (see equations in Support Protocol), we assume that the initial undiluted culture is 1
and that the second well, i.e., 1:3 of the initial culture, will be 0.33 and so on. If the reference culture, without suppressive
cells, produces 30% lysis of target cells at the fifth dilution, 1 liter.U.30 of the culture will be 0.0123 (1/81) of the
initial culture and the number of lytic units per culture will be 1/0.0123 = 81. At the same time, if a culture containing
suppressive cells produces 30% lysis of target cells at the third dilution, 1 liter.U.30 of this experimental culture will
be 0.11 (1/9) of the initial culture and the number of lytic units per culture will be 1/0.11 = 9. The % L.U.30 of the
experimental culture in relation to the reference culture will therefore be 9/81 × 100 = 11%.
also be reported as absolute number of cells by counting the cells in the wells of culture
plates before dilution.
BASIC
PROTOCOL 6
MEASURING MYELOID CELL–DEPENDENT IN VIVO TOLERANCE BY
ADOPTIVE TRANSFER
Immune suppression can also be studied in vivo, and the method is certainly more
challenging than the in vitro setup. We previously presented a method (Marigo et al.,
2010; also see previous version of this unit; doi: 10.1002/0471142735.im1417s91) to
evaluate in vivo tolerance, by which normal healthy recipients were antigen stimulated
and where MDSCs were adoptively transferred. This protocol permits the evaluation
of tolerance in a situation of stimulation relatively free from the multiple variables
present during either tumor growth or infectious diseases. Instead, the protocol reported
below is extended to tumor-bearing mice where MDSCs are expanded in vivo, during
tumor development, and the antigen is expressed by the tumor and is cross-presented to
lymphocytes. The experiment must take into account at least three groups of animals: a
group of tumor-free mice, one of tumor bearing mice and a group of vaccinated tumor-
bearing mice (Ugel et al., 2012).
Materials
Dendritic cell (DC) preparation started 5 days before beginning this protocol
(Inaba, Swiggard, Steinman, Romani, Schuler, & Brinster, 2009)
EG7-OVA cells (ATCC no. CRL-2113TM) stably expressing OVA257-264
Serum-free RPMI 1640 medium (e.g., Invitrogen)
CD45.2+C57BL/6 mice purchased from Jackson Laboratories
RPMI containing 3% FBS (see recipe)
CD45.1+ transgenic OT-1 mice obtained in our animal facility by crossing the two
strains purchased from Jackson Laboratories
CD8α+ T cell isolation kit (Miltenyi Biotech)
RPMI containing 10% FBS (see recipe)
1 mg/ml LPS stock solution (Sigma, cat. no. L-4516)
10 mg/ml OVA257-264 peptide stock solution (available lyophilized from JPT
Peptide Technologies)Solito et al.
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Dulbecco’s phosphate-buffered saline (DPBS; Lonza BioWhittaker, cat. no.
BE17-515Q)
BD Golgi Stop (BD Biosciences)
FcR blocking reagent (clone 2.4G2, ThermoFisher)
Anti–mouse CD8 (i.e., PeCy5-anti CD8a, clone 53.6.7; ThermoFisher, Catalog #
15-0081-81)
Anti–mouse CD451.1 conjugated to a brilliant fluorochrome (i.e., PE-anti CD45.1,
clone A20; ThermoFisher, Catalog # 12-0453-81)
BD Cytofix/Cytoperm kit (BD Biosciences)
Anti–mouse IFN-γ (i.e., FITC-anti IFN-γ, clone XMG1.2; ThermoFisher, Catalog
# 11-7311-41) or rat IgG1 as isotype control (ThermoFisher)
50-ml conical tubes
1-ml syringe
18-G and 26-G needles
10-mm culture dish
2-ml syringe
Refrigerated centrifuge
Infrared heat lamp
Mouse restraining device
100-μm nylon-mesh cell strainer (BD Biosciences)
12-ml and 4-ml round-bottom tubes
48-well culture plate
96 well U-bottom microtiter plate
Microtiter plate carrier for centrifuge
LSRII flow cytometer (BD Biosciences)
FlowJo 7.6.5 Software (TreeStar)
Red cell ACK lysis buffer (Lonza)
Additional reagents and equipment for culturing dendritic cells Inaba et al., 2009),
harvesting spleens and other lymphoid organs from mice (Reeves & Reeves,
1992), counting viable cells by trypan blue exclusion (Strober, 2001), flow
cytometry, injection of mice, to prepare immunosuppressive cells (Basic
Protocol 1 or 2), euthanasia of mice (Reeves & Reeves, 1992), and flow
cytometric IFN-γ intracellular staining
NOTE: 5 days before starting, set up a dendritic cell (DC) culture from mouse bone
marrow as described in Inaba et al. (2009), which will be used to vaccinate some groups
of control mice.
Day 0
1. Collect EG7-OVA suspension cell line expressing OVA257-264 from 75-cm2 flasks in
a 50-ml conical tube.
2. Gently pipet cells up and down with a 1-ml syringe and an 18-G needle.
3. Load the syringe and tap bubbles, change the needle to a 26-G size.
4. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell
concentration (Strober, 2001).
5. Adjust EG7-OVA cell concentration to 10 × 106 cells/ml with serum-free RPMI
and inject 100 µl (106 EG7 cells) subcutaneously into the flank of at least 5 mice
per group of CD45.2+ C57BL/6 mice.
Also prepare uninjected controls.
Solito et al.
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Day 7
6. Collect spleens (Reeves & Reeves, 1992) from OT-1CD45.1+ mice in a small
volume of RPMI containing 3% FBS under sterile conditions.
7. Place spleens in a 10-mm culture dish with a small volume of RPMI containing 3%
FBS and gently disaggregate using the plunger of a 2-ml syringe.
8. Add 5 ml of RPMI containing 3% FBS to cells and collect the cells in a 50-ml conical
tube by gently pipetting. Repeat until the spleen pulp is completely disaggregated.
9. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
10. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell
concentration (Strober, 2001).
11. Prepare CD8+ T cells by means of CD8α+ T cell isolation kit from Miltenyi Biotech.
Alternatively, the whole spleen of the OT-1 CD41.1+ mouse could be used without any
sorting. Determine abundance of CD8+ T cells by means of cytometric staining with anti-
CD8 and anti-Vα2 Vβ5.1/5.2, and collect an amount of total splenocytes that corresponds
to 5× 106 CD8+/Vα2 Vβ5.1/5.2 cells.
12. Wash enriched CD8+ T cells with at least 10 ml fresh serum-free RPMI 1640
medium twice, each time by centrifuging cells 6 min at 300 ×g, 4°C, and carefully
discarding the supernatant.
13. Resuspend cells in a small volume of serum-free RPMI.
14. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell
concentration (Strober, 2001).
15. Adjust concentration to 25× 106 cells/ml with serum-free RPMI, place cells in a
50-ml conical tube, and put the tube on ice.
16. Warm CD45.2+C57BL/6 mice under an infrared heat lamp for about 10 min.
Do not overheat mice, and do not exceed the correct number of mice per cage during
warming steps.
17. Gently pipet cells up and down with a 1-ml syringe and a 18-G needle.
18. Load the syringe, change the needle to a 26-G size, and tap bubbles out.
Take care to eliminate bubbles thoroughly; otherwise, mice might die from air embolism.
19. Place the mouse in the restraining device and inject 200 μl of cell suspension (5 ×
106 cells/mouse in the tail vein).
For randomization purposes, label mice before cell injection and keep them together in
the same cage.
Day 8
DC maturation
20. Gently remove supernatant medium from the DC culture. Take care to avoid scraping
the plate while removing the supernatant.
21. Feed cells with 1 ml of 10RPMI/10% FBS medium containing 1 μg/ml LPS (add
from 1 mg/ml stock) and 2 μg/ml OVA257-264 peptide (add from 10 mg/ml stock).
22. Incubate the cell culture at 37°C, in a 5% CO2 incubator.
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Day 9
DC preparation
23. Gently remove cells from plate culture, washing wells several times with DPBS,
and transfer cell suspension to a 50-ml conical tube.
24. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
25. Wash cell pellet by adding 10 ml serum-free RPMI; repeat steps 19 and 20 twice.
26. Resuspend mature DC preparation in a small volume of serum-free RPMI.
27. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell
concentration (Strober, 2001).
28. Adjust concentration to 10 × 106 cells/ml with serum-free RPMI, place cells in a
50-ml conical tube, and put them on ice.
29. Check mature DC preparation by flow cytometry for CD11c expression and MHC
II and CD80/CD86 up-regulation relative to immature DCs, as described in Inaba
et al., (2009).
Perform DC vaccination
This procedure is used as a control to make sure that the in vivo tolerance is maintained
in the presence of further stimulation of CD8+ T lymphocytes.
30. Gently pipet mature DCs up and down with a 1-ml syringe and 18-G needle.
31. Load the syringe, change the needle to a 26-G size, and tap to remove bubbles.
32. Inoculate 100 μl of DC suspension subcutaneously into each mouse flank.
Day 14
Lymph node cell preparation
33. Euthanize mice and collect inguinal, axillary, and brachial lymph nodes (Reeves &
Reeves, 1992) from both sides in a small volume of RPMI/3% FBS in a 48-well
plate, separately for each mouse.
34. Put lymph nodes on a nylon mesh and disaggregate mechanically with the plunger
from a 2-ml syringe.
35. Let disaggregated cells pass through the nylon mesh, washing with 5 ml of RPMI
containing 3% FBS. Repeat steps 34 and 35 for every lymph node until complete
disaggregation is achieved.
36. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
Aspiration of supernatant with a glass Pasteur pipet attached to a vacuum pump minimizes
cell loss.
37. Add 10 ml of RPMI/10% FBS to wash pellet.
38. Centrifuge the suspension 6 min at 300 ×g, 4°C, and discard the supernatant.
39. Resuspend cell pellet in a small volume of RPMI/10% FBS and filter through a
nylon mesh into a 12-ml round-bottom tube.
40. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell
concentration (Strober, 2001).
41. Adjust concentration to 5 × 106 cells/ml with RPMI/10% FBS and place cells on
ice. Solito et al.
23 of 42
Current Protocols in Immunology
Lymph node cell staining
42. Plate lymph node cell suspension in 100 μl of RPMI/10% FBS per well of a 96-well
U-bottom microtiter plate.
Usually, 12 replicates, subdivided into 6 wells for specific-peptide stimulation and 6
wells for either unstimulated or unrelated peptide-stimulated control culture, should be
sufficient.
43. Add 100 μl of RPMI/10% FBS containing 2 μg/ml OVA257-264 peptide (add from
10 mg/ml stock) to half of the wells and 100 μl of RPMI/10% FBS without peptide
(or unrelated peptide) to the other half.
IL-2 could be also added, at a final concentration of 20 U/ml, to each well to increase
the signal in subsequent flow cytometric analysis.
44. Incubate plate at 37°C, in a 5% CO2 incubator 6 to 8 hr before Golgi stop treatment.
Ex vivo peptide stimulation must be carried out for at least 18 hr, and BD Golgi Stop
treatment should not exceed 8 to 12 hr. It may be necessary to initially test and coordinate
these concomitant steps in the initial setup experiments.
BD Golgi stop incubation
45. Prepare sufficient 11× BD Golgi Stop stock solution according to the manufac-
turer’s instructions in RPMI/10% FBS and distribute among the wells of the plate at
20 μl/well.
The BD Golgi Stop datasheet suggests using 4 μl for 6 ml (final volume); hence, to fill
an entire plate, prepare 1.986 ml of RPMI/10% FBS medium and add 14.7 μl BD Golgi
Stop.
46. Incubate 8 to 12 hr at 37°C, in a 5% CO2 incubator.
Day 15
47. Transfer the cells to new 4-ml round-bottom tubes.
48. Wash samples once in DPBS, centrifuge the suspension 6 min at 300 ×g, 4°C, and
discard the supernatant.
49. Resuspend cell pellets in 200 μl DPBS and plate 100 μl of cell suspension in
duplicate on a new 96-well U-bottom microtiter plate.
It is necessary to split every sample into two aliquots in order to stain them with IFN-γ -
specific antibody and matched isotype control. Remember to save a small aliquot of each
sample and pool together. These extra samples will be used to perform single staining
controls.
50. Centrifuge the plate in a microtiter plate carrier 2 min at 300 ×g, 4°C, and discard
the supernatant by decanting.
51. Incubate the cells with 2 μg of FcR blocking reagent (2.4G2 mAb), in a volume of
50 μl per well of DPBS for 20 min at room temperature.
It may be necessary to titrate the antibody to determine the appropriate amount.
52. Stain cells with 50 μl DPBS per well containing anti-CD8-PeCy5 (0.5 μl) and
anti-CD45.1-PE (0.1 μl) for 20 min at 4°C.
Remember to include appropriate single-staining controls. It may be necessary to titrate
the antibodies.
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53. Wash samples once with 100 μl/well DPBS, centrifuge the suspension 6 min at
300 ×g, 4°C, and discard the supernatant. Repeat washing with 200 μl DPBS,
centrifuging under the same conditions.
54. Add 100 μl/sample Fixation/Permeabilization solution (from BD Cytofix/Cytoperm
kit), and gently resuspend with a multichannel pipettor. Incubate 20 min at 4°C.
55. Wash samples once with 100 μl of 1× BD Perm/Wash buffer (from BD
Cytofix/Cytoperm kit), centrifuge the plate 2 min at 300 ×g, 4°C, and discard
the supernatant. Repeat washing with 100 μl of 1× BD Perm/Wash buffer and
decant the supernatants.
56. Stain cells with 50 μl BD Perm/Wash buffer containing in our case rat anti–mouse
IFN-γ FITC (0.75 μl/well) or rat IgG1 FITC isotype control (0.75 μl/well) for 30
min at 4°C.
Remember to include appropriate single staining controls. It may be necessary to titrate
antibody amount.
57. Wash samples once with 100 μl 1× BD Perm/Wash buffer, centrifuge the plate 2
min at 300 ×g, 4°C, and discard the supernatant by decanting. Repeat washing with
100 μl 1× BD Perm/Wash buffer, and centrifuge again as before.
In order to detect intracellular IFN-γ , gate cells first by their morphology, and then
collect as many events as possible in the CD8+/CD45.1+ gate. After the acquisition,
proceed with data analysis. For each sample, either stained with specific antibody or
isotype control, provide the same gating schema, taking care to adapt gates for minor
changes. Gate cells by morphology and identify CD8+CD45.1+ populations. Inside this
gate, set a baseline gate on negative IFN-γ staining using the isotype control, and copy
this gate to the sample stained with the specific antibody, in order to determine the
percentage of IFN–γ -releasing lymphocytes.
BASIC
PROTOCOL 7
IDENTIFICATION AND SORTING OF HUMAN M-MDSC CELLS FROM
PERIPHERAL BLOOD (PB) OF CANCER PATIENTS TO MEASURE THEIR
IMMUNOSUPPRESSIVE ACTIVITY
The aim of this protocol is to obtain CD14+ cells enriched for M-MDSCs from PB of
cancer patients, and to preserve their functional activity in order to use them for in vitro
functional assays. PBMCs are obtained after centrifugation and sedimentation of whole
blood on a Ficoll gradient (see Mandruzzato et al., 2009).
The selection of fluorochrome-labeled antibodies to identify M-MDSCs has to be per-
formed based on optimal signal strength and minimal spectral overlap; the optimal
concentration of each antibody must be evaluated in titration experiments.
Materials
Anticoagulated whole blood obtained from cancer patients
Sorting buffer (see recipe)
Human FcR blocking reagent (Miltenyi Biotec)
CD14 FITC (clone M5E2, BD Biosciences)
HLA-DR APC (clone L243, BD Biosciences)
Complete IMDM medium (see recipe)
15- and 50-ml polypropylene conical tubes
Refrigerated centrifuge
12 × 75–mm polypropylene tubes pre-coated for at least 1 hr with heat-inactivated
fetal bovine serum (FBS)
Solito et al.
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Figure 3 Gating strategy for the definition of M-MDSCs in human PBMCs. PBMCs were labeled with anti-CD14,
anti-HLA-DR, and anti-CD124, and then analyzed by flow cytometry. After a morphological gate on PBMCs and
doublets exclusion, monocytes were gated as CD14+ cells, and then the gate for HLA-DRlow cells and CD124+
cells was set based on the FMO control.
Additional reagents and equipment for isolating PBMC from whole blood
(Mandruzzato et al., 2009) and counting viable cells (Strober, 2001)
NOTE: All the procedures, including sorting, are performed at 4°C, to avoid cell loss and
adherence to the plastic.
Determination of M-MDSCs expression level on PBMCs
The following antibodies were used to characterize blood M-MDSCs in melanoma
(Damuzzo et al., 2016) and meningioma (Pinton et al., 2018) patients: CD14-FITC, HLA-
DR-APC and CD124 PE. As the down-regulation of HLA-DR and CD124 expression
are important parameters to determine two subsets of M-MDSCs, it is important to use
FMO controls to define HLA-DR and CD124 gates as shown in Figure 3. The protocol
for PB-M MDSC staining is described below:
1. Isolate PBMCs from whole blood of cancer patients (see Mandruzzato et al., 2009).
Collect cells in 12 × 75–mm tubes for FACS analysis and wash them with sorting
buffer. Centrifuge 6 min at 300 × g, 4°C, and discard the supernatant.
2. After the centrifugation, tubes are subsequently incubated with Fc-receptor blocking
reagent diluted 1/25 at 4°C for 10 min.
3. Add the mixture of antibodies (CD14/HLA-DR/CD124) to the tubes in a final
volume of 100 μl sorting buffer and incubate at 4°C for 20 min.
Common mAbs used for characterization of human CD11blow/- BM-MDSCs and PB
M-MDSCs are listed in Table 2.
4. At the end of the incubation time, wash cells with sorting buffer. Centrifuge the
suspension for 6 min at 300 × g, 4°C, and discard the supernatant.
5. Resuspend samples in 250 μl of sorting buffer, and proceed with flow cytometric
acquisition and analysis.
Solito et al.
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Flow cytometry analysis of PB M-MDSCs
An example of gating strategy, analyzed with FlowJo 7.6.5 software, is shown in Figure 3.
The expression of HLA-DR and CD124 markers is evaluated on CD14+ whole monocytes
cells gated on singlet cells and on the basis of FMO signal.
Separation of PB M-MDSCs
6. Stain whole PBMCs (isolated from blood of cancer patients; see step 1) with anti-
CD14 and anti-HLA-DR antibodies using the same staining protocol described
above. Specifically, for FACS analysis, cells are stained in 12 × 75–mm polypropy-
lene tubes pre-coated for at least 1 hr with heat-inactivated fetal bovine serum
(FBS).
7. After labeling, filter cells through a 100-µm cell strainer and isolate CD14+/HLA-
DRlow cells by FACS sorting.
Sorting conditions (nozzle, pressure, voltage at the deflection plates, cell rate) should be
set up in order to assure maximal monocyte viability after separation. To this purpose,
the staining of monocytes with a viability dye 24 and 48 hr after cell sorting is strongly
recommended in order to ascertain that a lack in the immunosuppressive activity is real
and not influenced by cell death.
8. After the separation, wash and resuspend PB M-MDSCs in 10 ml of complete
IMDM. Properly dilute aliquots of the single-cell suspension with trypan blue solu-
tion and estimate the number of viable cells (Strober, 2001).
FACS sorting of CD124+/CD14+ M-MDSCs is challenging due to low intensity
and unimodal expression of CD124. Therefore, in patients with an expansion of
CD124+/CD14+M-MDSCs, total monocyte fraction can be isolated by immunomagnetic
sorting using anti-CD14 microbeads (Miltenyi Biotec) and the manufacturer’s protocol.
In this case, it would be better to test more than one monocyte: T cell ratio, in order to
avoid a lack of immunosuppressive activity due to a high dilution of M-MDSCs in the
culture.
BASIC
PROTOCOL 8
HUMAN BM-MDSC GENERATION
MDSCs can also be expanded in vitro starting from bone marrow (BM) cell aspirate
from healthy donors, as previously described (Marigo et al., 2010), using the protocol
described below. Specifically, we culture BM cells depleted of T, B and NK cells for
4 days with recombinant human (rh) G-CSF and GM-CSF. At the end of the culture,
a heterogeneous cell culture is obtained, enriched for BM-MDSCs that are contained
in the most immature fraction (Solito et al., 2011b). To purify BM-MDSCs, the cell
culture is depleted of the most mature myeloid cells (CD11b+) to obtain CD11blow/-
BM-MDSCs.
Materials
Bone marrow aspirates (see information in step 1)
10× red blood cell lysis buffer (see recipe)
Complete IMDM (see recipe; FBS should be previously tested in order to
guarantee a proper proliferation of BM-MDSCs)
Sorting buffer (see recipe)
Human CD3 Microbeads (Miltenyi Biotec)
Human CD19 Microbeads (Miltenyi Biotec)
Human CD56 Microbeads (Miltenyi Biotec)
Human CD11b Microbeads (Miltenyi Biotec)
Human FcR blocking reagent (Miltenyi Biotec Catalog #130-059-901)
CD11b-PE (clone Bear1, Beckman Coulter)
CD16-FITC (clone REA423, Miltenyi Biotec) Solito et al.
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Anti–CD3 mAb (optional)
Anti–CD19 mAb (optional)
Anti–CD56 mAb (optional)
100-μm nylon-mesh cell strainer (BD Biosciences)
15- and 50-ml polypropylene conical tubes
Refrigerated centrifuge
LD column (Miltenyi Biotec)
MACS separator (Miltenyi Biotec)
LSRII flow cytometer (BD Biosciences)
FlowJo 7.6.5 Software (TreeStar)
24-well tissue culture plate
12 × 75–mm tubes
Additional reagents and equipment for counting cells (Strober, 2001)
Isolation of BM-MDSCs
1. Samples are obtained from BM aspiration both from pediatric patients with normal
cytologic characteristics and from adult patients undergoing orthopedic implants.
Blood aspirates are collected in tubes containing K2EDTA for BM from adults and
sodium citrate for pediatric BM. Samples are filtered through a 100-µm cell strainer
into 50-ml polypropylene tubes, and red blood cells are removed using a hypotonic
solution of ammonium chloride (red blood cell lysis buffer).
The amount of the lysis buffer and the incubation time may be optimized on the basis
of BM source. As an alternative source to obtain MDSCs, it is possible to use cultured
stem cells (CD34+ cells), which are available from different companies (e.g., AllCell). In
our experience, the in vitro differentiation induces the acquisition of immunosuppressive
activity and MDSC-associated markers in the cell population that down-regulates the
CD34 marker.
2. Wash the cells with complete IMDM. Centrifuge 6 min at 300 × g, 4°C, and discard
the supernatant.
3. Resuspend cells in 10 ml of complete IMDM.
4. Dilute an aliquot of suspension in trypan blue solution, and determine viable cell
concentration (Strober, 2001).
5. Incubate 107 BM cells in 40 μl of sorting buffer with a mix containing
20 μl of CD3 microbeads, 20 μl of CD19 microbeads, and 20 μl of CD56 mi-
crobeads at 4°C for 15 min.
Proportionally scale up the amount of sorting and staining buffer and microbeads on the
basis of total number of cells that need to be depleted. For less than 107 BM cells keep
the same amount of reagents.
6. Wash the cells with sorting buffer, centrifuge 6 min at 300 × g, 4°C, aspirate the
supernatant and resuspend the pellet in 500 μl of sorting buffer, then proceed with
magnetic separation as described below. For more details, see the protocol from
Miltenyi Biotec for magnetic separation with LD columns.
7. Place LD column in the magnetic field of a suitable MACS separator and prepare
the column by rinsing it with 2 ml of sorting buffer.
8. Apply cell suspension onto the column; collect unlabeled cells that pass through and
wash the column twice with 1 ml of sorting buffer.
9. Wash cells with 10 ml complete IMDM.Solito et al.
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10. Resuspend cells in 10 ml of complete IMDM and dilute an aliquot of suspension in
trypan blue solution, and determine viable cell concentration (Strober, 2001).
11. Take an aliquot of cell suspension and check the enrichment of the myeloid subsets
by flow cytometric analysis.
Assess the loss of the lymphocyte region from depleted BM-myeloid cells. The assessment
of the morphological features of the depleted samples through flow cytometry may be
sufficient for many applications. For transcriptomic analysis, stain depleted myeloid
cells with a mixture of antibodies containing anti-CD3/CD19/CD56. For the details of
the staining protocol, see Basic Protocol 7.
12. Plate cells (2 × 106 cells per well) into a 24-well tissue culture plate in complete
IMDM in the presence of rhG-CSF and rhGM-CSF (40 ng/ml) for 4 days, at 37°C
with 8% CO2.
During this period, it may be useful to observe cells, in order to monitor their growth.
Usually it is not necessary to split cultures unless the growth (signaled by medium turning
yellow) is excessive. The presence of small areas rich in clusters of myeloid cells with
granular aspect indicates that G-CSF/GM-CSF treatment is supporting myeloid survival
and proliferation, since this morphology is not present in untreated cultures.
Isolation of CD11blow/-BM-MDSCs
13. After 4 days, harvest cell cultures in 50-ml polypropylene tubes and wash them with
complete IMDM. Dilute an aliquot of the single-cell suspension with trypan blue
solution, and estimate the number of viable cells (Strober, 2001).
Usually, the number of viable BM-MDSCs recovered is around 60% of the initial number
of plated cells, while recovery of CD11blow/- cells is 6% to 7% of total BM-MDSCs after
G-CSF/GM-CSF treatment.
14. Incubate 107cells in 80 μl of sorting buffer with 20 μl of CD11b microbeads at 4°C
for 15 min.
Scale up the amount of sorting buffer and CD11b microbeads on the basis of total number
of cells that need to be depleted. For less than 107 BM cells, keep the same amount of
reagents.
15. Wash the cells with sorting buffer, centrifuge 6 min at 300 × g, 4°C, aspirate the
supernatant, and resuspend the pellet in 500 μl of sorting and straining buffer.
Perform magnetic separation as described below. For more details, see the protocol
from Miltenyi Biotec for magnetic separation with LD columns.
16. Place LD column in the magnetic field of a suitable MACS separator and prepare
the column by rinsing it with 2 ml of sorting buffer.
17. Apply cell suspension onto the column; collect unlabeled cells that pass through and
wash the column twice with 1 ml of sorting buffer.
18. Wash cells with complete IMDM.
19. Resuspend cells in 10 ml of complete IMDM and dilute an aliquot of suspension in
trypan blue solution, and determine viable cell concentration (Strober, 2001).
The number of viable cells recovered depends on the cellularity and maturation profile
of the BM, but the range is usually between 105 and 5 × 106 CD11blow/- cells.
20. Check the loss of the most mature myeloid cells from the cell culture by flow
cytometry (Fig. 4). Collect cells in 12 × 75–mm tubes for FACS analysis and wash
with sorting buffer. Centrifuge 6 min at 300 × g, 4°C, and discard the supernatant.
Solito et al.
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Figure 4 MDSC generation and separation from human BM cells cultured in vitro. The first two plots show the
morphology of human BM cells before (A) and after (B) lymphocyte depletion. Lymphocyte-depleted BM cells
are then cultured for 4 days with 40 ng/ml G-CSF and GM-CSF to generate BM-MDSCs. The maturation profile
is characterized by the CD16 and CD11b markers as shown in (C). The most immature subset of BM-MDSCs,
identified as CD11blow/–/CD16–, is then separated by immunomagnetic sorting using anti-CD11b microbeads (D).
21. Incubate the tubes with Fc-receptor blocking reagent diluted 1/25 at 4°C for 10 min.
Add the mixture of antibodies (CD11b/CD16) to the tubes and incubate at 4°C for
20 min. Adjust the volume of staining mix to 100 μl with sorting buffer.
Common mAbs used for characterization of human CD11blow/- BM-MDSCs and PB
M-MDSCs are listed in Table 2.
22. At the end of the incubation time, wash the cells with sorting buffer. Centrifuge the
suspension 6 min at 300 × g, 4°C, and discard the supernatant.
23. Resuspend the cells in 250 μl of sorting buffer and perform flow cytometric acqui-
sition and analysis.
Flow cytometry analysis of CD11blow/-BM-MDSCs
Figure 4 shows an example of lymphocyte depletion and the gating strategy for CD11blow/-
BM-MDSC isolation, analyzed with FlowJo 7.6.5 Software.
BASIC
PROTOCOL 9
EVALUATION OF THE SUPPRESSION INDUCED BY HUMAN MDSC ON
THE PROLIFERATION OF T CELLS STIMULATED BY ANTI-CD3/ANTI-
CD28 AND MEASURED BY CELL TRACE DILUTION
Immune suppression exerted by MDSCs on activated T cells can be measured in terms
of inhibition of T cell proliferation. The method can be applied to complex experiments
for large-scale screenings, and takes into consideration a basic property of myeloid-
dependent suppression: the ability to induce proliferative arrest of actively dividing cells.
Materials
Anti-CD3 (0.6 to 5 µg/ml) clone OKT3, obtained after expansion and purification
of a commercially available hybridoma
Dulbecco’s phosphate-buffered saline (DPBS without Ca and Mg; Lonza
BioWhittaker, cat. no. BE17-515Q)
Complete IMDM medium (see recipe)
Immunosuppressive (myeloid) cells, e.g., PB M-MDSCs or CD11blow/-
BM-MDSCs (Basic Protocol 7 and 8)
5 µg/ml anti-CD28, clone CD28.2 BioLegend, Catalog #302923)
PBMC from healthy donors (see Mandruzzato et al., 2009, for isolation technique)
CellTraceTM Violet Cell Proliferation Kit (Molecular Probes)Solito et al.
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Fetal bovine serum (FBS; Gibco or Sigma-Aldrich); FBS used for functional assay
should be tested to be sure that immunosuppression is detectable and not
overcome by an excessive T cell proliferation
Human FcR blocking reagent (Miltenyi Biotec Catalog #130-059-901)
Sorting buffer (see recipe)
CD3-conjugated to a brilliant fluorochrome (i.e., PC7-anti CD3, clone UCHT1,
Catalog # 737657, Beckman Coulter)
24-, 96-, or 384-well flat-bottom microtiter plate
50-ml polypropylene conical tubes (BD Falcon)
Refrigerated centrifuge
TruCount tubes (Becton Dickinson)
LSRII flow cytometer (BD Biosciences)
FlowJo 7.6.5 Software (TreeStar)
Additional reagents and equipment to prepare immunosuppressive cells (Basic
Protocol 7 and 8), and to count viable cells by trypan blue exclusion (Strober,
2001)
Day 0: Culture plate coating
1. Prepare sufficient coating buffer with anti-CD3 (0.6 to 5 μg/ml final concentration
in DPBS).
Antibody concentration may be optimized on the basis of stock and supplier.
Usually, we prefer to perform titrations by testing four or five concentrations of anti-CD3
mAb. As an example, it is possible to monitor T cell proliferation by culturing the cells
for 4 days in the presence of 5, 2.5, 1.2 and 0.6 μg/ml of anti-CD3. Additionally, it is
useful to perform these titration experiments in the presence of suppressive cells, in order
to be sure to choose the concentration of anti-CD3 that allows a good proliferation of
CD3+ cells and at the same time makes it possible to appraise suppression of T cell
proliferation.
2. Fill 96-well flat-bottom microtiter plates with 200 μl/well of the coating buffer
using a multichannel pipettor. Alternatively, fill 384-well flat-bottom microtiter
plates with 80 μl/well coating buffer with a multichannel pipettor. Fill an equal
number of wells with 200 μl/well or 80 μl/well of DPBS without antibodies, for
background proliferation measurement.
Also, remember to fill extra wells for appropriate controls based on the experimental
setup, e.g., suppressive cells only.
3. Incubate the plate overnight at 4°C or alternatively at 37°C for 1 hr.
4. Fill every well with 200 μl/well (96-well plate) or 80 μl/well (384-well plate) of
IMDM medium using a multichannel pipettor and empty the plate by inverting it
with a rapid movement. Repeat at least two times, to wash the wells extensively.
Fill the plate from the top of the well to avoid scratching the surface of the well, which
might alter the antibody coating.
5. Incubate the plate for 1 hr with 200 μl/well or 80 μl/well of complete IMDM
medium containing 10% FBS. After incubation and two washes of the plate with
medium, the plate is ready for the assay.
Day 1: Cell plating
Plate immunosuppressive cells
6. Prepare PB- derived M-MDSCs (Basic Protocol 7) or CD11blow/- BM-MDSCs
(Basic Protocol 8) or other strategies of enrichment. Wash the cells with complete
medium. Solito et al.
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The supernatant should be aspirated from the top; be careful to remove as much super-
natant as possible without disturbing the cell pellet.
7. After counting cells with trypan blue (Strober, 2001), resuspend them in a suitable
volume of 150 μM arginine RPMI containing 10% FBS to adjust cell concentration.
The concentration will depend upon the design of the experiment. A good range of
MDSCs is 50% of the total culture cellularity. If 1× 105 anti-CD3/CD28 PBMCs are
used in a 96-well plate, MDSC concentration can be adjusted to 2× 106/ml, so that
1× 105cells will be plated in 50 μl (50% of total cultured cells). Alternatively, 0.25 ×
105 anti-CD3/CD28 PBMCs can be used in 384-well plate, and MDSC concentration
can be adjusted to 1.25× 106/ml, so that 0.25× 105cells will be plated in 20 μl (50% of
total cultured cells).
8. Work in sterility, empty the 96-well microtiter plate or 384-well microplate (from
step 5) by inverting it with a rapid movement.
9. Immediately plate suppressive cells in triplicate or duplicate for specific and back-
ground proliferation in 50 μl/well (96-well plate) or 20 μl/well (384-well plate),
and place the microtiter plate in a 37°C, 5% CO2 incubator.
When organizing the distribution of samples, avoid using the outer wells, because these
wells are more susceptible to evaporation. Outer wells can be filled with sterile DPBS
or medium. Remember to fill at least three wells with 10% medium without suppressive
cells; these wells will be used as control cultures for the determination of background
proliferation. Multiply these control wells for the different treatments according to the
experimental setup, e.g., different inhibitors and drugs to be tested.
Prepare responder PBMCs
10. Thaw PBMCs of healthy donors in complete IMDM medium, under sterile con-
ditions and dilute an aliquot of suspension in trypan blue solution, and determine
viable cell concentration (Strober, 2001).
11. Adjust the concentration of PBMCs to 2 × 107 cells/ml in DPBS and the concen-
tration of CellTrace to 2× in DPBS; quickly mix equal volumes of PBMCs and
CellTrace and incubate for 5 min at 37°C. Add 1/5 of the total volume of FBS,
centrifuge 6 min at 300 ×g, 4°C, and plate stained PBMCs at a concentration of
3× 106 cells/well in a 24-well plate with complete IMDM medium containing 10%
FBS.
The concentration of CellTrace depends on the stock of the reagent and the sensitivity
of cells used for the staining, and the reagent should be titrated upon arrival. Usually a
range of 0.5 to 2 μM is used.
12. Incubate CellTrace+ PBMCs for at least 1 hr in incubator at 37°C, and check the
incorporation by flow cytometry.
To evaluate CellTrace incorporation, the control of autofluorescence value of unstained
PBMCs should be included to evaluate whether the difference of emission signals among
unstained PBMCs and CellTrace+ PBMCs is enough to quantify a sustained proliferation,
represented by a strong dilution of CellTrace signal.
13. Harvest PBMCs, count them (Strober, 2001), adjust their concentration at 2 × 106
cells/ml for a 96-well plate or 1.25× 106 cells/ml for a 384-well plate in 150 μM
arginine RPMI containing 10% FBS. Plate them in triplicate or duplicate for specific
and background proliferation in 100 μl/well (96-well plate) or 20 μl/well (384-well
plate).
Pay attention to the cell distribution scheme. PBMCs will proliferate upon anti-CD3/anti-
CD28 stimulation, and their proliferation will be inhibited by immunosuppressive cells;
therefore, PBMCs should be distributed in previously anti-CD3-coated wells, either withSolito et al.
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or without immunosuppressive cells, as test and reference wells, respectively. Reference
wells will contain 1× 105 (96-well plate) or 0.25×105 anti-CD3/CD28-activated PBMCs
(384-well plate). The proliferative behavior of MDSCs alone under these conditions
should also be tested; therefore, MDSCs will be cultured with additional 100 μl (96-well
plate) or 40 μl (384-well plate) of medium instead of anti-CD3/CD28-activated PBMCs.
14. Add 1 µl/well (96-well plate) or 0.4 μl/well (384-well plate) of soluble anti-CD28
(5 µg/ml). Adjust the volume of each well to 200 μl (96-well plate) or 80 μl (384-
well plate), and place the microtiter plate in a 37°C, 5% CO2 incubator for four
days.
Day 4
Culture harvesting
15. Pool triplicates or duplicates in new 4-ml round-bottom tubes, wash samples once
with sorting and staining buffer, centrifuge the suspension 6 min at 300 ×g, 4°C,
and discard the supernatant.
16. Block nonspecific binding with 25 μl FcR blocking reagent for 10 min at 4°C.
17. Stain cells with anti-CD3 (see Table 2) for 20 min at 4°C; in addition, anti-CD4 and
CD8 can be added to antibody mix together with anti-CD3 mAb in the same tube,
in order to analyze immunosuppression among CD4 and CD8 subsets. Adjust the
volume of staining mix to 100 μl with sorting and staining Buffer.
The optimal concentration of CD3, CD4, and CD8 must be evaluated in titration experi-
ments, by analyzing the positive and negative signal of the antibody staining after using
seven different concentrations (starting from twice the concentration recommended by
the datasheet, dilute 1:2 six times). Remember to include appropriate single-staining
controls. The use of anti-CD3 conjugated to a brilliant fluorochrome is recommended in
order to clearly distinguish proliferating T cells (that have diluted CellTrace signal) from
CellTrace-negative myeloid cells that often present an autofluorescence higher than that
of T cells.
18. Wash samples once with sorting and staining buffer, centrifuge the suspension for
6 min at 300 ×g, 4°C, and discard the supernatant.
19. Resuspend samples in 250 μl DPBS, transfer the mix in TruCount tubes, gently
vortex them, and proceed with flow cytometric acquisition and analysis.
Flow cytometry analysis
20. Perform flow cytometry acquisition and analysis.
To detect CD3+ proliferating T cells, gate cells first by morphology, and then collect a
sufficient number of events in the CD3+/CellTrace+ gate. After the acquisition, proceed
with data analysis. Gate cells on morphology and identify CD3+CellTrace+ population.
Inside this gate, set a baseline gate on the histograms of CellTrace signal of unstimulated
PBMC control, and copy this gate to the stimulated PBMCs cultured in the presence or
absence of M-MDSCs, in order to determine the percentage of proliferating T lympho-
cytes. With FlowJo software, it is possible to model proliferation data; FlowJo presents
a graphical display as well as information about each generation in the subset. The
proliferation platform also provides information about the fraction of cells from the orig-
inal population that have divided, and the number of times these cells have divided. In
addition, the FlowJo Proliferation Platform draws gates that separate each generation.
21. Proliferation of T cells is evaluated by assessing the signal of CellTrace on CD3+
cells, and considering as proliferating the cells present from generation G2 onwards
(see Fig. 5 panel A), or calculating the absolute number of CD3+cells in each sample
using TruCount tubes. In both cases, data are normalized assuming the proliferation
of T cells cultured alone as 100%. Solito et al.
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Figure 5 Representative examples of two different ways to evaluate immunosuppression. The
left plot of panel (A) represents the overlay between CellTrace profile of activated T cells
(a-T cells) cultured alone (black peak) or in the presence of MDSCs (white peak). This graph
allows to appreciate the increase in the number of undivided cells (higher CellTrace fluorescence)
in the presence of MDSCs as compared to T cells alone. This type of immunosuppression was
defined as “qualitative” and is quantified by FlowJo proliferation tool, considering as “proliferating”
the T lymphocytes belonging to generation G2 onwards and comparing these percentages in
the absence (middle plot) or in the presence (right plot) of MDSCs. The histogram in panel (B)
instead shows the reduced number of CD3+ T cells quantified by TruCount tubes when activated
T cells are cultured in the presence of MDSCs. This type of immunosuppression is defined as
“quantitative.”
REAGENTS AND SOLUTIONS
150 μM arginine RPMI containing 10% FBS
Arginine-free RPMI (Biological Industries, Kibbutz Beit Haemek, Israel),
supplemented with:
150 μM arginine
10% FBS
10 U/ml penicillin and streptomycin
0.01 M HEPES
Store up to 3 days at 4°C
Complete IMDM medium
Iscove’s Modified Dulbecco’s Medium (IMDM; Gibco Invitrogen) supplemented
with:
10% heat-inactivated FBS (Gibco)
0.01 M HEPES
0.55 mM arginine (Sigma-Aldrich)
0.24 mM asparagine (Sigma-Aldrich)
1.5 mM glutamine (Sigma-Aldrich)Solito et al.
34 of 42
Current Protocols in Immunology
100 U/ml penicillin/streptomycin
1× 2-mercaptoethanol
Store up to 3 days at 4°C
Red blood cell lysis buffer, 10×
0.15 M NH4Cl
0.01 mM KHCO3
0.1 mM disodium EDTA
Store up to 6 months at 4°C
RPMI medium containing 3%, 5%, and 10% FBS
RPMI 1640 medium (e.g., Invitrogen) supplemented with:
3%, 5%, or 10% fetal bovine serum (FBS)
1× sodium pyruvate (e.g., Invitrogen)
1× penicillin-streptomycin (e.g., Invitrogen)
1× L-glutamine (e.g., Invitrogen)
1× 2-mercaptoethanol (e.g., Invitrogen)
Store up to 3 days at 4°C
Sorting buffer
Dulbecco’s phosphate-buffered saline (DPBS; Lonza BioWhittaker, cat. no.
BE17-515Q) containing:
0.5% (w/v) bovine serum albumin (BSA; Sigma-Aldrich, cat. no. A4503)
2 mM disodium EDTA
Store up to 7 days at 4°C
Staining buffer
Supplement Dulbecco’s phosphate-buffered saline (DPBS; Lonza BioWhittaker, cat.
no. BE17-515Q) to 0.5% (w/v) with bovine serum albumin (BSA; Sigma-Aldrich,
cat. no. A4503). Store up to 7 days at 4°C.
COMMENTARY
Background Information
The definition of MDSCs has been and
is the subject of many studies and many re-
views. It is becoming increasingly clear that
a simple phenotypic analysis is not suffi-
cient to define one or more MDSC subsets,
especially in human patients (Bronte et al.,
2016; Damuzzo et al., 2015; De Sanctis et al.,
2016b; Solito et al., 2014). Initial efforts to
harmonize their phenotype have demonstrated
a large complexity and variance in the defi-
nition of all MDSC subsets, with the largest
variance within the PMN subsets (Mandruz-
zato et al., 2016), and it is essential to com-
bine their phenotype with a functional assay
or with a biochemical and molecular charac-
terization, in order to prove their characteristic
key element, which is their suppressive ability.
In fact, the ability to suppress T cell prolifer-
ation and activation is considered the “gold
standard” for defining MDSCs (Bronte et al.,
2016).
MDSCs restrain the immune response
through many different mechanisms. MD-
SCs can block lymphocyte proliferation by
depleting amino acids critically needed for
their fitness. Indeed, they can reduce the
level of cysteine through altered transport
(Srivastava, Sinha, Clements, Rodriguez, &
Ostrand-Rosenberg, 2010) and activate en-
zymes like indoleamine 2,3-dioxygenase1
(IDO1), which catabolizes l-tryptophan to
kynurenines (Orabona et al., 2011), arginase 1
(ARG1), to produce ornithine, and urea or/and
nitric oxide synthase 2 (NOS2), to generate ni-
tric oxide (Bronte et al., 2005). The nutrient de-
privation results in T cell proliferation arrest.
Moreover, it has been reported that through the
action of ARG1 and NOS2, which could act
separately or in a combined fashion, l-arginine
metabolism affects different T cell molecular
pathways, such as translational control of the ζ-
chain of CD3 and blockade of the JAK/STAT5
signaling cascade (Bronte et al., 2005).
Solito et al.
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Furthermore, activation of NOS2 by MD-
SCs induces the generation of nitric oxide
(NO), as well as reactive oxygen species
(ROS) and peroxinitrites (RNS). These short-
lived compounds induce the nitration of dif-
ferent targets such as chemokines and TCR,
which contribute to blocking T cell migration
and cytotoxic effect against tumor, cause T cell
apoptosis, and inhibit production of cytokines
such as IL-2, which is fundamental for T cell
antitumor functions (De Sanctis et al., 2014;
Molon et al., 2011; Nagaraj et al., 2007).
MDSCs at the tumor site can increase the
expression of programmed death ligand 1/2
(PD-L1/2) on their membrane surface, which
can drastically down-regulate an anti-tumor
T cell–mediated reactivity by interacting with
the receptor expressed on tumor-infiltrating T
cells such as programmed death 1 (PD-1). In-
deed, in a mouse model of ovarian cancer,
exhaustion of tumor-infiltrating lymphocytes
correlated with the expression of PD-L1/2
by tumor cells and tumor-derived myeloid
cells. However, treatments combining vac-
cines (or costimulatory antibodies) with an-
tibodies blocking PD-1 or PD-L1, but not PD-
L2, were able to expand the antigen-specific
CD8+ T cells and trigger tumor rejection (Du-
raiswamy, Freeman, & Coukos, 2013). Fur-
thermore, it was demonstrated that PD-L1
up-regulation on MDSCs is transcriptionally
induced by the hypoxia-inducible factor-1α
(HIF-1α) at the tumor site. Blocking PD-L1
decreases MDSC-mediated T cell suppression
under hypoxia by down-regulating IL-6 and
IL-10 produced by MDSCs (Noman et al.,
2014). In this respect, recent clinical trials with
PD-1/PD-L1 blockade therapy have shown un-
precedented durable response in patients with
a variety of cancers despite only a minor-
ity of patient benefits from such therapy; for
these reasons, several studies are investigat-
ing the contributions of PD-L1 signaling dur-
ing checkpoint blockade therapy, especially to
examine the cell populations that respond to
PD-L1. Very recently, PD-L1 in tumor cells
has been shown to be dispensable for the re-
sponses to PD-L1 blockade therapy after tu-
mor establishment in three different models
(MC38, A20, and E.G7). Moreover, PD-L1
appeared not only to be highly expressed in
myeloid cells, but also to contribute to the inhi-
bition of T cell activation, since blocking PD-
L1 signaling by Ab releases such inhibition,
leading to better T cell activation (Tang et al.,
2018). Recently, we analyzed the mechanisms
involved in the interplay between MDSCs and
activated T cells. We found that activated T
cells release IL-10 following interaction with
MDSCs which, in turn, induce STAT3 phos-
phorylation on MDSCs, then leading to PD-L1
expression. Moreover, we observed that the
expression of ligands PD-L1 and MHC class
II on in vitro–induced MDSCs or on MDSCs
from tumor microenvironment of melanoma
patients is related to an increased expression
of their respective receptors, PD-1 and LAG-3,
on T cells, the inhibitory molecules associated
with T cell dysfunctions (Pinton et al., 2016).
The immune response can also be tuned
by MDSCs supporting the generation of
other suppressive cells. MDSCs promote ex-
pansion of Treg through mechanisms not
completely understood, which likely include
CD40-CD40L interactions, TGFβ and IL-
10 release and direct antigen presentation,
and the expression of ARG1 (Gabrilovich,
Ostrand-Rosenberg, & Bronte, 2012; Ser-
afini, Mgebroff, Noonan, & Borrello, 2008).
Moreover, MDSCs promote macrophage re-
programming toward an M2 phenotype typi-
cal of tumor associated macrophages (TAMs)
through cell-cell contact cross-talk. IL-10 pro-
duced by MDSCs induces a reduced ability
by macrophages to produce IL-2, which in
turn stimulates IL-10 production by MDSCs
(Sinha, Clements, Bunt, Albelda, & Ostrand-
Rosenberg, 2007). The altered balance
between IL-12/IL-10 in the tumor microen-
vironment skews T cell immunity toward a
tumor-promoting Type 2 response and de-
creases DC maturation, which is critical for
priming T lymphocyte responses (Ostrand-
Rosenberg, Sinha, Beury, & Clements, 2012).
Many interactions, similarities, and rela-
tionships between MDSCs and TAMs are
emerging, which require clarification. Indeed,
it has been advanced that MDSCs and TAMs
employ different mechanisms to control im-
mune responses, but the possibility that some
MDSC subsets might give rise to TAMs com-
plicates separation of these two cell types, es-
pecially within the tumor environment (Sica
et al., 2007; Ugel, De Sanctis, Mandruzzato,
& Bronte, 2015).
In this unit, we report some protocols to
accurately test the suppressive abilities of iso-
lated mouse and human M-MDSCs on T lym-
phocytes. The accuracy and reproducibility
with which immunosuppressive measures are
carried out become fundamental when drug
tests are required for the development of ther-
apeutic approaches to counteract MDSC func-
tions.Solito et al.
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We present three methods to evaluate, ei-
ther in vitro or in vivo, immune suppression
by myeloid cells isolated from mice to the
detriment of CD8+ T lymphocytes. The pro-
liferation assay using flow cytometry can be
easily performed in many laboratories, in par-
ticular to evaluate the proliferation in response
to antigen-specific stimuli. Proliferation as-
says by [3H]TdR incorporation represent a
very simple and robust method to quantita-
tively evaluate the suppressive activity on T
cells effected by a nonspecific stimulus (anti-
CD3 and anti-CD28 mAbs) to compare many
different treatments. On the other hand, these
assays can be easily modified to assess al-
loantigen stimulation (Marigo et al., 2010;
also see previous version of this unit; doi:
10.1002/0471142735.im1417s91).
Basic Protocol 1, with its simplicity, could
be useful to assess large numbers of experi-
mental conditions, such as large screenings of
new drugs, or when limited amounts of cells, as
in the case of rare populations, are available.
It must be pointed out, however, that it only
provides information about T cell prolifera-
tion but is completely blind to the lymphocyte
effector function.
Microcultures with myeloid suppressors,
followed by evaluation of cytolytic activity by
51Cr release, offer the possibility to investi-
gate T cell–specific effector function and its
modulation/inhibition by immunomodulatory
cells, both preserving the simplicity of prolif-
eration assay and allowing the investigator to
work with numerous variables and rare cell
populations, which could be difficult to es-
tablish under complex in vivo conditions. The
chromium release assay is even more labori-
ous than the [3H]TdR uptake assay, but offers
a more specific and extended readout. Lytic
unit transformation, which measures the ex-
tent of suppression normalized to the internal
control without suppressive cells, provides a
more straightforward representation of the re-
sults and allows the comparison and averaging
of results from different experiments. Evalua-
tion of L.U. represents a more effective mea-
sure than either the proliferation assay or sin-
gle effector-to-target ratio cytotoxicity value,
since it includes an estimation of both func-
tional activity (cytolytic activity of cultures)
and cell proliferation (number of cells recov-
ered in each culture).
Basic Protocol 6 makes it possible to
study tolerogenic activity of immunosuppres-
sive populations in vivo. It could be demand-
ing in terms of time and cost, since it requires
a consistent number of immunosuppressive
cells per mouse and only allows the inves-
tigator to process a few experimental condi-
tions within a single experiment. Flow cyto-
metric evaluation of the expression of both
CD8 and CD45.1 markers in the context of
a CD45.2+ recipient mouse makes it possible
to carefully estimate the relative abundance of
transferred T cells within the total CD8+ T cell
number in the sample; this assessment could
provide information about elimination and/or
proliferative blockade of the antigen-specific
CD8+ T cells promoted by the immunosup-
pressive mouse environment. The percentage
of CD8+/CD45.1+ cells could also be used to
calculate the total amount of CD8+/CD45.1+
cells per recipient mouse, taking into account
the total number of cells obtained from ex-
planted lymph nodes. Moreover, intracellular
staining of IFN-γ will provide a measurement
of the activation state of transferred effector
cells.
It is not clear whether MDSCs isolated
from tumor-free naı¨ve mice are immunosup-
pressive (Bronte, 2009; Greifenberg et al.,
2009; Ribechini, Leenen, & Lutz, 2009). It
appears that the assay used might influence
the extent of suppression. The use of arti-
ficially high numbers of MDSC subsets in
vitro might unveil inhibitory properties that are
intrinsic to these subpopulations, but which
will not be manifest in vivo. In particular,
a strong activation of effector T cells (such
as that induced by antibodies or alloantigens)
might also trigger inhibitory pathways in naı¨ve
myeloid cells. In this sense, the proliferation
assay reported here tends to overestimate the
immunosuppressive strength. In our experi-
ence, the in vitro parameter that better cor-
relates with the immunosuppressive activity
of in vivo–transferred myeloid cells is the ca-
pability of these cells to inhibit the effector
function of antigen-specific T cells in micro-
cultures when added at low percentages (1%
to 6% of total cells in culture), as previously
described (Dolcetti et al., 2010).
We have discussed protocols for both in
vitro and in vivo assays based on the use of
specific TCR transgenic CD8+ T cells, but it
is clear that these protocols can be adapted
to other combinations of TCRs and mouse
backgrounds, provided that preliminary exper-
iments are performed to establish the amount
of DCs necessary to induce priming of trans-
ferred CD8+ T cells. Moreover, in the assays
described here, we primarily used naı¨ve CD8+
T cells, but memory/effector T cells could be Solito et al.
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isolated from previously primed mice or easily
obtained by a previous, short-term stimulation
of naı¨ve CD8+ T cells with the antigenic pep-
tide in the absence of myeloid suppressors.
Basic Protocols 7, 8 and 9 describe pro-
cedures to identify the expansion of human
monocytic MDSCs and isolate them from the
peripheral blood of cancer patients, as well
as to expand CD11blow/- BM-MDSCs in vitro
and purify MDSCs in order to evaluate their
suppressive function, a mandatory property
to define myeloid subsets as MDSCs (Bronte
et al., 2016). In some cases, these myeloid
populations can increase in response to tumor-
derived factors released in the tumor microen-
vironment, and the opportunity to monitor
their level in whole blood through flow cy-
tometry might contribute to give them a prog-
nostic value. Flow cytometry analysis of PB-
isolated M-MDSCs is rapid and requires a
small amount of cells, thus allowing preser-
vation of all the material obtained from whole
blood for cell separation and suppression as-
say.
Critical Parameters and
Troubleshooting
For the reasons discussed in Background
Information, the most important parameter to
consider in evaluating the suppressive activ-
ity of myeloid cells is the amount of cells re-
quired to give a complete inhibition of the in
vitro assay. Although this principle applies to
the in vivo assay, technical limitations might
preclude in vivo titration as well.
It is of capital importance to make use of
excellent-quality FBS in all cultures; in our
experience, sera need to be relatively low in
growth factors, since their abundance could
interfere with suppressive activity by myeloid
cells by simply activating/differentiating MD-
SCs. It is our practice to screen different lots
of FBS to ensure that they do not interfere
with the suppressive assay. Briefly, we com-
pare the new FBS batches with the one cur-
rently in use in the lab by setting up the
suppressive assays described in Basic Pro-
tocols 3 and 5 for mouse cells and Basic
Protocol 9 for human cells. We select the FBS
batch used for cultures whose suppressive ac-
tivity was similar to those containing the pre-
vious FBS. Also, attention should be given
to the red cell lysis step, since it has been
reported that hemoglobin can scavenge nitric
oxide (Azarov et al., 2005), altering suppres-
sive phenomena that rely on NOS2 and ARG1
activity. Some articles report immunosuppres-
sive assays in which T cell proliferation is ob-
tained using beads coated with anti-CD3 and
anti-CD28 antibodies. This stimulation needs
to be carefully considered, because it has been
recently demonstrated that it could lead to ar-
tifactual T lymphocyte suppression due to se-
questration of beads and their phagocytosis by
MDSCs (Davis, Silvin, & Allen, 2017).
Cell density is a critical parameter for mi-
crocultures; thus, particular attention should
be paid to cell counts, dilutions, and plating.
It is useful to check the percentage of CD8+
T cells that are positive for Vα2 Vβ5.1/5.2 in
transgenic OT-1 total spleen, and adjust the
dilution rate of OT-1 cells to feeder C57Bl/6
cells, in order to obtain the proper state of ac-
tivation after 5 days of culture.
Latent immunosuppressive programs might
be artificially activated either by sorting pro-
cedures or in vitro manipulation, a possibility
that must be considered for all separating pro-
cedures based on antibodies binding to surface
molecules. Relevant changes in the amount of
either mAbs or beads used for cell sorting of
MDSCs should thus be tested accurately, espe-
cially in view of the demonstration that some
antibodies such as anti-Gr-1 mAb can trigger
a signaling cascade in target cells (Ribechini
et al., 2009).
Critical parameters in in vivo experiments
are usually the number of transferred cells
and the proper preparation/maturation of DCs.
Moreover, the quality of transferred cells re-
quires attention; sometimes, these cells are
very sticky and tend to form clumps, and i.v. in-
oculation of clumped cells might compromise
recipient mouse survival. Maintaining cells on
ice during i.v. inoculation prevents clump for-
mation; clumps could also be disaggregated
with gentle pipetting, carefully avoiding dam-
age to cells with small-gauge needles.
Antigen specificity is another issue related
to the very same biology of suppressor cells
that, as with other cellular inhibitors of
immune responses, seems to act through both
antigen-specific and nonspecific mechanisms
(Solito, Bronte, & Mandruzzato, 2011a). We
and others favor the idea that the immune-
suppressive mechanisms of MDSCs do not
require direct presentation of the antigen,
even though this might be a rate-limiting step
under some experimental conditions where
the encounter with rare CD8+ T cells in lymph
nodes might be favored by direct antigen pre-
sentation. Although the immune-suppressive
mechanisms are mostly antigen-independent,
antigen activation is mandatory since MDSCs
do not affect resting T cells. The protocols
described here can be adapted to evaluateSolito et al.
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direct antigen presentation by carefully puls-
ing MDSCs, antigen-presenting cells, or both
with either relevant or irrelevant antigenic
peptides.
It is interesting to note that prolifera-
tion/suppression can be evaluated by quanti-
fying the absolute T cell number, and/or by
CellTrace profile. In fact, over the years, we
have observed, in mouse and human exper-
iments, that in some cases suppression ap-
pears as a reduction in the absolute num-
ber of T cells (quantitative suppression) and
sometimes as a delay in the CellTrace profile
(qualitative suppression). Sometimes MDSC-
mediated immune suppression is both qualita-
tive and quantitative, but in many cases, it is
one or another (see Fig. 5). Therefore, it would
be better to routinely use CellTrace-based pro-
liferation together with the count of absolute
numbers of T cells with a standard procedure
based on TruCount tube, thus ensuring the pos-
sibility of evaluating both. All these consider-
ations suggest that would be important to stan-
dardize the conditions for MDSC phenotyping
and suppression within and across laboratories
in order to define minimal essential criteria en-
abling reproducible results.
Anticipated Results
The advent of multi-parameter flow cy-
tometry has greatly enhanced the possibility
to better characterize the expanded and
infiltrating myeloid subsets in cancer models
and patients. Moreover, the chance to isolate
highly purified immune suppressive subsets by
FACS sorting, in addition to immunomagnetic
methods, gives us the opportunity to facilitate
downstream studies, for example through
the characterization of their transcriptome to
define molecular targets. Immunosuppressive
assays based on CellTrace dilution evaluated
by FACS methods are technically very accu-
rate and can be easily reproduced in different
laboratories.
[3H]Thymidine incorporation in a 96-well
plate usually produces a readout of about 150–
200 × 103 cpm, while the negative controls fall
on the order of 1/100 of the stimulated cells. A
properly developed control microculture could
induce the lysis of about 70% to 90% of tar-
get cells. Usually, the first and second dilu-
tion of the culture will be at plateau, and the
lysis curve should reach half of the plateau
at about fourth-fifths dilution, achieving the
baseline at the seventh dilution. Nonspecific
lysis should be <30% in the first dilutions
and rapidly reach background at the third dilu-
tion. Nonspecific lysis may be proportional to
specific lysis, and instead of subtracting back-
ground from specific lysis, it could be a bet-
ter approach to minimize nonspecific lysis uti-
lizing a different target cell line that is less
sensitive to NK activity. If lytic unit represen-
tation is chosen, it could also be informative
to take a look at the line plot for each sam-
ple, in order to assure proper regression of
the results and the consistency of estimated
L.U.
A proper immunization with DCs will re-
sult in the accumulation of CD8+/CD45.1+
cells to represent 2% to 6% of total
lymph node cellularity. More than 60% of
CD8+/CD45.1+-gated cells should be positive
for IFN-γ staining. The samples that have not
received ex vivo peptide stimulation usually do
not give high background staining compared
to matched isotype control.
Time Considerations
The protocols presented here are quite time
consuming, and they also require incubations
lasting several days. The presented strategy
for mouse MDSC enrichment takes 3 hr to
be completed, while the strategy for human
M-MDSCs isolation from peripheral blood
takes 5 hr. CellTrace proliferation assays,
[3H]TdR proliferation assay, and the 51Cr re-
lease test setup can be completed in at a cou-
ple of hours for simple experiments, but could
take longer depending on the number of differ-
ent conditions that need to be tested. [3H]TdR
readout could be completed in less than
1 hr, taking into account the quenching period,
while the CellTrace proliferation assay takes
2 hr. Chromium release can be more time
consuming, since target cell pulsing usually
needs 1.5 hr to complete pulsing, washing,
and cell counting. Dilution of CTL cultures
could be performed during target pulsing, and,
usually, the setup of a commonly sized experi-
ment with 15 to 20 different experimental con-
ditions in triplicate could be completed within
the time of pulsing. After 5 hr of effector/target
co-culture, the supernatant transfer could take
at least 30 min. LumaPlates need to be read
the following day.
In vivo experiments are quite demanding;
challenging steps usually include the achieve-
ment of a suitable amount of suppressive
cells, which could take several hours of sort-
ing, and the single-recipient processing of
lymph nodes, which could take about 6 hr
for a simple experiment with about 20 re-
cipients. Flow cytometric acquisition could
also take a long time, depending on the Solito et al.
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frequency of CD8+CD45.1+ events to be
collected.
Recently, it has emerged that the immuno-
suppressive mechanisms mediated by MDSCs
could be different for different tumors. In the
future, it may be necessary to reevaluate the
technical measures to optimize the isolation of
MDSCs and standardize the appropriate func-
tional tests by comparing the districts where
these cells are present and different tumor
types (Damuzzo et al., 2015; Kumar, Patel,
Tcyganov, & Gabrilovich, 2016).
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